Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Gynecology

  Free Subscription


Articles published in Gynecol Oncol

Retrieve available abstracts of 380 articles:
HTML format
Text format



Single Articles


    May 2017
  1. WOLF B, Ganzer R, Stolzenburg JU, Hentschel B, et al
    Extended mesometrial resection (EMMR): Surgical approach to the treatment of locally advanced cervical cancer based on the theory of ontogenetic cancer fields.
    Gynecol Oncol. 2017 May 16. pii: S0090-8258(17)30845.
    PubMed     Text format     Abstract available


  2. PARK JY, Seong SJ, Kim TJ, Kim JW, et al
    Significance of body weight change during fertility-sparing progestin therapy in young women with early endometrial cancer.
    Gynecol Oncol. 2017 May 16. pii: S0090-8258(17)30807.
    PubMed     Text format     Abstract available


  3. BARBER EL, Doll KM, Gehrig PA
    Hospital readmission after ovarian cancer surgery: Are we measuring surgical quality?
    Gynecol Oncol. 2017 May 15. pii: S0090-8258(17)30851.
    PubMed     Text format     Abstract available


  4. EDMONDSON RJ, Crosbie EJ, Nickkho-Amiry M, Kaufmann A, et al
    Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative.
    Gynecol Oncol. 2017 May 13. pii: S0090-8258(17)30853.
    PubMed     Text format     Abstract available


  5. COHEN JG, Prendergast E, Geddings JE, Walts AE, et al
    Evaluation of venous thrombosis and tissue factor in epithelial ovarian cancer.
    Gynecol Oncol. 2017 May 10. pii: S0090-8258(17)30802.
    PubMed     Text format     Abstract available


  6. GARCIA C, Yao A, Camacho F, Balkrishnan R, et al
    A SEER-Medicare analysis of the impact of metformin on overall survival in ovarian cancer.
    Gynecol Oncol. 2017 May 9. pii: S0090-8258(17)30847.
    PubMed     Text format     Abstract available


  7. TANENBAUM LM, Mantzavinou A, Subramanyam KS, Del Carmen MG, et al
    Ovarian cancer spheroid shrinkage following continuous exposure to cisplatin is a function of spheroid diameter.
    Gynecol Oncol. 2017 May 9. pii: S0090-8258(17)30795.
    PubMed     Text format     Abstract available


  8. ENG KH, Morrell K, Starbuck K, Spring-Robinson C, et al
    Prognostic value of miliary versus non-miliary sub-staging in advanced ovarian cancer.
    Gynecol Oncol. 2017 May 8. pii: S0090-8258(17)30844.
    PubMed     Text format     Abstract available


  9. DE DONATO M, Petrillo M, Martinelli E, Filippetti F, et al
    Uncovering the role of nuclear Lysyl oxidase (LOX) in advanced high grade serous ovarian cancer.
    Gynecol Oncol. 2017 May 8. pii: S0090-8258(17)30806.
    PubMed     Text format     Abstract available


  10. GRABOSCH S, Tseng G, Edwards RP, Lankes HA, et al
    Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study.
    Gynecol Oncol. 2017 May 5. pii: S0090-8258(17)30787.
    PubMed     Text format     Abstract available


  11. BEAMAN KD, Dambaeva S, Katara GK, Kulshrestha A, et al
    The immune response in pregnancy and in cancer is active and supportive of placental and tumor cell growth not their destruction.
    Gynecol Oncol. 2017 May 3. pii: S0090-8258(17)30800.
    PubMed     Text format     Abstract available


  12. ESSEL KG, Bruegl A, Gershenson DM, Ramondetta LM, et al
    Salvage chemotherapy for gestational trophoblastic neoplasia: Utility or futility?
    Gynecol Oncol. 2017 May 2. pii: S0090-8258(17)30798.
    PubMed     Text format     Abstract available


  13. MENDERES G, Bonazzoli E, Bellone S, Black J, et al
    SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression.
    Gynecol Oncol. 2017 May 1. pii: S0090-8258(17)30804.
    PubMed     Text format     Abstract available


    April 2017
  14. HOLMAN LL, Pal N, Iglesias DA, Soliman PT, et al
    Factors prognostic of survival in advanced-stage uterine serous carcinoma.
    Gynecol Oncol. 2017 Apr 29. pii: S0090-8258(17)30799.
    PubMed     Text format     Abstract available


  15. KONG Y, Yang J, Jiang F, Zhao J, et al
    Clinical characteristics and prognosis of ultra high-risk gestational trophoblastic neoplasia patients: A retrospective cohort study.
    Gynecol Oncol. 2017 Apr 28. pii: S0090-8258(17)30791.
    PubMed     Text format     Abstract available


  16. COLON-OTERO G, Weroha SJ, Foster NR, Haluska P, et al
    Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers.
    Gynecol Oncol. 2017 Apr 28. pii: S0090-8258(17)30801.
    PubMed     Text format     Abstract available


  17. LEE J, Lin JB, Chang CL, Jan YT, et al
    Prophylactic lower para-aortic irradiation using intensity-modulated radiotherapy mitigates the risk of para-aortic recurrence in locally advanced cervical cancer: A 10-year institutional experience.
    Gynecol Oncol. 2017 Apr 27. pii: S0090-8258(17)30797.
    PubMed     Text format     Abstract available


  18. VENERIS JT, Darcy KM, Mhawech-Fauceglia P, Tian C, et al
    High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer.
    Gynecol Oncol. 2017 Apr 26. pii: S0090-8258(17)30793.
    PubMed     Text format     Abstract available


  19. CANTRELL LA, Backes F
    Highlights from the Society of Gynecologic Oncology 2017 Annual Meeting on Women's Cancer.
    Gynecol Oncol. 2017 Apr 26. pii: S0090-8258(17)30772.
    PubMed     Text format    


  20. BOOKMAN MA, Tyczynski JE, Espirito JL, Wilson TW, et al
    Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer.
    Gynecol Oncol. 2017 Apr 26. pii: S0090-8258(17)30792.
    PubMed     Text format     Abstract available


  21. PETERS ML, Garber JE, Tung N
    Managing hereditary breast cancer risk in women with and without ovarian cancer.
    Gynecol Oncol. 2017 Apr 25. pii: S0090-8258(17)30794.
    PubMed     Text format     Abstract available


  22. BAKER WD, Pierce SR, Mills AM, Gehrig PA, et al
    Nonoperative management of atypical endometrial hyperplasia and grade 1 endometrial cancer with the levonorgestrel intrauterine device in medically ill post-menopausal women.
    Gynecol Oncol. 2017 Apr 18. pii: S0090-8258(17)30776.
    PubMed     Text format     Abstract available


  23. KATCHMAN BA, Chowell D, Wallstrom G, Vitonis AF, et al
    Autoantibody biomarkers for the detection of serous ovarian cancer.
    Gynecol Oncol. 2017 Apr 17. pii: S0090-8258(17)30775.
    PubMed     Text format     Abstract available


  24. PHILLIPS A, Balega J, Nevin J, Singh K, et al
    Reporting 'Denominator' data is essential for benchmarking and quality standards in ovarian cancer.
    Gynecol Oncol. 2017 Apr 12. pii: S0090-8258(17)30786.
    PubMed     Text format     Abstract available


  25. EMI BRETSCHNEIDER C, Bensen JT, Geller EJ, Gehrig PA, et al
    Perioperative sexual interest in women with suspected gynecologic malignancies.
    Gynecol Oncol. 2017 Apr 12. pii: S0090-8258(17)30771.
    PubMed     Text format     Abstract available


  26. DEL CARMEN MG, Annunziata CM, Rice LW
    The clinical trials crisis in gynecologic oncology.
    Gynecol Oncol. 2017 Apr 11. pii: S0090-8258(17)30773.
    PubMed     Text format    


  27. SHINN EH, Valentine A, Baum G, Carmack C, et al
    Comparison of four brief depression screening instruments in ovarian cancer patients: Diagnostic accuracy using traditional versus alternative cutpoints.
    Gynecol Oncol. 2017 Apr 8. pii: S0090-8258(17)30240.
    PubMed     Text format     Abstract available


  28. SIDDIQUI MK, Tyczynski J, Pahwa A, Fernandes AW, et al
    Objective response rate is a possible surrogate endpoint for survival in patients with advanced, recurrent ovarian cancer.
    Gynecol Oncol. 2017 Apr 7. pii: S0090-8258(17)30770.
    PubMed     Text format     Abstract available


  29. GRAYBILL WS, Pothuri B, Chase DM, Monk BJ, et al
    Poly(ADP-ribose) polymerase (PARP) inhibitors as treatment versus maintenance in ovarian carcinoma.
    Gynecol Oncol. 2017 Apr 6. pii: S0090-8258(17)30724.
    PubMed     Text format    


  30. BAIOCCHI G, de Brot L, Faloppa CC, Mantoan H, et al
    Is parametrectomy always necessary in early-stage cervical cancer?
    Gynecol Oncol. 2017 Apr 6. pii: S0090-8258(17)30769.
    PubMed     Text format     Abstract available


  31. SZENDER JB, Papanicolau-Sengos A, Eng KH, Miliotto AJ, et al
    NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer.
    Gynecol Oncol. 2017 Apr 6. pii: S0090-8258(17)30726.
    PubMed     Text format     Abstract available


  32. GARCIA-SOTO AE, Schreiber T, Strbo N, Ganjei-Azar P, et al
    Cancer-testis antigen expression is shared between epithelial ovarian cancer tumors.
    Gynecol Oncol. 2017 Apr 6. pii: S0090-8258(17)30765.
    PubMed     Text format    


  33. NITSCHMANN CC, Multinu F, Bakkum-Gamez JN, Langstraat CL, et al
    Vaginal vs. robotic hysterectomy for patients with endometrial cancer: A comparison of outcomes and cost of care.
    Gynecol Oncol. 2017 Apr 6. pii: S0090-8258(17)30203.
    PubMed     Text format     Abstract available


  34. CREASMAN WT, Ali S, Mutch DG, Zaino RJ, et al
    Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol.
    Gynecol Oncol. 2017 Apr 6. pii: S0090-8258(17)30233.
    PubMed     Text format     Abstract available


  35. EYSBOUTS YK, Massuger LF, IntHout J, Lok CA, et al
    The added value of hysterectomy in the management of gestational trophoblastic neoplasia.
    Gynecol Oncol. 2017 Apr 5. pii: S0090-8258(17)30234.
    PubMed     Text format     Abstract available


  36. HAVRILESKY LJ, Moss HA, Chino J, Myers ER, et al
    Mortality reduction and cost-effectiveness of performing hysterectomy at the time of risk-reducing salpingo-oophorectomy for prophylaxis against serous/serous-like uterine cancers in BRCA1 mutation carriers.
    Gynecol Oncol. 2017 Apr 5. pii: S0090-8258(17)30241.
    PubMed     Text format     Abstract available


  37. HEMMING ML, Wagner AJ, Nucci MR, Chiang S, et al
    YWHAE-rearranged high-grade endometrial stromal sarcoma: Two-center case series and response to chemotherapy.
    Gynecol Oncol. 2017 Apr 5. pii: S0090-8258(17)30237.
    PubMed     Text format     Abstract available


  38. LI H, Sheng Y, Zhang Y, Gao N, et al
    MicroRNA-138 is a potential biomarker and tumor suppressor in human cervical carcinoma by reversely correlated with TCF3 gene.
    Gynecol Oncol. 2017 Apr 3. pii: S0090-8258(17)30062.
    PubMed     Text format     Abstract available


  39. SONG T, Kim MK, Jung YW, Yun BS, et al
    Minimally invasive compared with open surgery in patients with borderline ovarian tumors.
    Gynecol Oncol. 2017 Apr 2. pii: S0090-8258(17)30235.
    PubMed     Text format     Abstract available


  40. SEAGLE BL, Kanis M, Kocherginsky M, Strauss JB, et al
    Stage I uterine carcinosarcoma: Matched cohort analyses for lymphadenectomy, chemotherapy, and brachytherapy.
    Gynecol Oncol. 2017;145:71-77.
    PubMed     Text format     Abstract available


  41. SEAGLE BL, Sobecki-Rausch J, Strohl AE, Shilpi A, et al
    Prognosis and treatment of uterine leiomyosarcoma: A National Cancer Database study.
    Gynecol Oncol. 2017;145:61-70.
    PubMed     Text format     Abstract available


  42. HERZOG TJ, Cohn DE
    Dose Dense Chemotherapy for Front-line Ovarian Cancer Treatment: The Price is Right?
    Gynecol Oncol. 2017;145:1-2.
    PubMed     Text format    


  43. RODRIGUEZ-GARCIA A, Minutolo NG, Robinson JM, Powell DJ, et al
    T-cell target antigens across major gynecologic cancers.
    Gynecol Oncol. 2017 Apr 1. pii: S0090-8258(17)30725.
    PubMed     Text format     Abstract available


    March 2017
  44. WARREN JL, Harlan LC, Trimble EL, Stevens J, et al
    Trends in the receipt of guideline care and survival for women with ovarian cancer: A population-based study.
    Gynecol Oncol. 2017 Mar 31. pii: S0090-8258(17)30232.
    PubMed     Text format     Abstract available


  45. SALANI R, Khanna N, Frimer M, Bristow RE, et al
    An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations.
    Gynecol Oncol. 2017 Mar 31. pii: S0090-8258(17)30238.
    PubMed     Text format     Abstract available


  46. PARK JY, Kim DY, Suh DS, Kim JH, et al
    Analysis of outcomes and prognostic factors after fertility-sparing surgery in malignant ovarian germ cell tumors.
    Gynecol Oncol. 2017 Mar 31. pii: S0090-8258(17)30239.
    PubMed     Text format     Abstract available


  47. BARBER EL, Dusetzina SB, Stitzenberg KB, Rossi EC, et al
    Variation in neoadjuvant chemotherapy utilization for epithelial ovarian cancer at high volume hospitals in the United States and associated survival.
    Gynecol Oncol. 2017 Mar 30. pii: S0090-8258(17)30230.
    PubMed     Text format     Abstract available


  48. LIU CY, Elias KM, Howitt BE, Lee LJ, et al
    Sentinel lymph node mapping reduces practice pattern variations in surgical staging for endometrial adenocarcinoma: A before and after study.
    Gynecol Oncol. 2017 Mar 28. pii: S0090-8258(17)30227.
    PubMed     Text format     Abstract available


  49. SCOTT SA, van der Zanden C, Cai E, McGahan CE, et al
    Prognostic significance of peritoneal cytology in low-intermediate risk endometrial cancer.
    Gynecol Oncol. 2017 Mar 27. pii: S0090-8258(17)30228.
    PubMed     Text format     Abstract available


  50. DRIVER JA, Viswanathan AN
    Frailty measure is more predictive of outcomes after curative therapy for endometrial cancer than traditional risk factors in women 60 and older.
    Gynecol Oncol. 2017 Mar 27. pii: S0090-8258(17)30226.
    PubMed     Text format     Abstract available


  51. BREGAR A, Deshpande A, Grange C, Zi T, et al
    Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors.
    Gynecol Oncol. 2017 Mar 24. pii: S0090-8258(17)30207.
    PubMed     Text format     Abstract available


  52. CHAM S, Huang Y, Tergas AI, Hou JY, et al
    Utility of radiation therapy for early-stage uterine papillary serous carcinoma.
    Gynecol Oncol. 2017 Mar 23. pii: S0090-8258(17)30204.
    PubMed     Text format     Abstract available


  53. JANDIAL DA, Brady WE, Howell SB, Lankes HA, et al
    A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2017 Mar 21. pii: S0090-8258(17)30229.
    PubMed     Text format     Abstract available


  54. RUTLEDGE TL, Kano M, Guest D, Sussman A, et al
    Optimizing endometrial cancer follow-up and survivorship care for rural and other underserved women: Patient and provider perspectives.
    Gynecol Oncol. 2017 Mar 18. pii: S0090-8258(17)30225.
    PubMed     Text format     Abstract available


  55. K AU K, Peterson N, Truesdell P, Reid-Schachter G, et al
    CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer.
    Gynecol Oncol. 2017 Mar 16. pii: S0090-8258(17)30208.
    PubMed     Text format     Abstract available


  56. JESKE YW, Ali S, Byron SA, Gao F, et al
    FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2017 Mar 14. pii: S0090-8258(17)30152.
    PubMed     Text format     Abstract available


  57. MCGEE J, Giannakeas V, Karlan B, Lubinski J, et al
    Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?
    Gynecol Oncol. 2017 Mar 14. pii: S0090-8258(17)30153.
    PubMed     Text format     Abstract available


  58. NASIOUDIS D, Kanninen TT, Holcomb K, Sisti G, et al
    Prevalence of lymph node metastasis and prognostic significance of lymphadenectomy in apparent early-stage malignant ovarian sex cord-stromal tumors.
    Gynecol Oncol. 2017 Mar 11. pii: S0090-8258(17)30205.
    PubMed     Text format     Abstract available


  59. WYSHAM WZ, Schaffer EM, Coles T, Roque DR, et al
    Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial.
    Gynecol Oncol. 2017 Mar 10. pii: S0090-8258(17)30160.
    PubMed     Text format     Abstract available


  60. COWAN RA, Eriksson AG, Jaber SM, Zhou Q, et al
    A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancer.
    Gynecol Oncol. 2017 Mar 9. pii: S0090-8258(17)30121.
    PubMed     Text format     Abstract available


  61. RADER JS, Sill MW, Beumer JH, Lankes HA, et al
    A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2017 Mar 9. pii: S0090-8258(17)30161.
    PubMed     Text format     Abstract available


  62. DE ROOIJ BH, Ezendam NP, Nicolaije KA, Caroline Vos M, et al
    Effects of Survivorship Care Plans on patient reported outcomes in ovarian cancer during 2-year follow-up - The ROGY care trial.
    Gynecol Oncol. 2017 Mar 7. pii: S0090-8258(17)30162.
    PubMed     Text format     Abstract available


  63. VAN BROEKHOVEN ME, de Rooij BH, Pijnenborg JM, Vos MC, et al
    Illness perceptions and changes in lifestyle following a gynecological cancer diagnosis: A longitudinal analysis.
    Gynecol Oncol. 2017 Mar 6. pii: S0090-8258(17)30157.
    PubMed     Text format     Abstract available


  64. LEE M, Kim EJ, Cho Y, Kim S, et al
    Predictive value of circulating tumor cells (CTCs) captured by microfluidic device in patients with epithelial ovarian cancer.
    Gynecol Oncol. 2017 Mar 5. pii: S0090-8258(17)30163.
    PubMed     Text format     Abstract available


  65. WANG YM, Wang CJ, Fang FM, Chen HC, et al
    Differences in the outcomes and complications between elderly and younger uterine cervical cancer patients treated by definitive radiotherapy - A propensity score-matched study.
    Gynecol Oncol. 2017 Mar 5. pii: S0090-8258(17)30155.
    PubMed     Text format     Abstract available


  66. COHN DE, Ko E, Meyer LA, Wright JD, et al
    The "value" of value in gynecologic oncology practice in the United States: Society of Gynecologic Oncology evidence-based review and recommendations.
    Gynecol Oncol. 2017 Mar 1. pii: S0090-8258(17)30145.
    PubMed     Text format    


    February 2017
  67. ALVAREZ RD, Fowler WC Jr
    The times they are a-changin' - Transformation of accreditation and certification in gynecologic oncology.
    Gynecol Oncol. 2017 Feb 27. pii: S0090-8258(17)30156.
    PubMed     Text format    


  68. FOX E, McCuaig J, Demsky R, Shuman C, et al
    Corrigendum to "The sooner the better: Genetic testing following ovarian cancer diagnosis" [Gynecol. Oncol. 137 (2015) 423-429].
    Gynecol Oncol. 2017 Feb 27. pii: S0090-8258(17)30142.
    PubMed     Text format    


  69. CHASE DM, Chaplin DJ, Monk BJ
    The development and use of vascular targeted therapy in ovarian cancer.
    Gynecol Oncol. 2017 Feb 23. pii: S0090-8258(17)30075.
    PubMed     Text format     Abstract available


  70. SAED GM, Diamond MP, Fletcher NM
    Updates of the role of oxidative stress in the pathogenesis of ovarian cancer.
    Gynecol Oncol. 2017 Feb 23. pii: S0090-8258(17)30154.
    PubMed     Text format     Abstract available


  71. KOMIYAMA S, Manrai M, Takahashi R, Takeya C, et al
    Safe dissection of high paraaortic lymph nodes superior to the renal vein in ovarian, primary peritoneal, or fallopian tube cancer by the "Komiyama's maneuver", a modification of Kocher's maneuver.
    Gynecol Oncol. 2017 Feb 22. pii: S0090-8258(17)30126.
    PubMed     Text format     Abstract available


  72. FELICES M, Chu S, Kodal B, Bendzick L, et al
    IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer.
    Gynecol Oncol. 2017 Feb 21. pii: S0090-8258(17)30149.
    PubMed     Text format     Abstract available


  73. BUTTARELLI M, Mascilini F, Zannoni GF, Ciucci A, et al
    Hormone receptor expression profile of low-grade serous ovarian cancers.
    Gynecol Oncol. 2017 Feb 20. pii: S0090-8258(17)30150.
    PubMed     Text format     Abstract available


  74. RING KL, Yemelyanova AV, Soliman PT, Frumovitz MM, et al
    Potential immunotherapy targets in recurrent cervical cancer.
    Gynecol Oncol. 2017 Feb 20. pii: S0090-8258(17)30148.
    PubMed     Text format     Abstract available


  75. SIOULAS VD, Schiavone MB, Kadouri D, Zivanovic O, et al
    Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?
    Gynecol Oncol. 2017 Feb 18. pii: S0090-8258(17)30144.
    PubMed     Text format     Abstract available


  76. ETHIER JL, Desautels DN, Templeton AJ, Oza A, et al
    Is the neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic cancers? A systematic review and meta-analysis.
    Gynecol Oncol. 2017 Feb 17. pii: S0090-8258(17)30147.
    PubMed     Text format     Abstract available


  77. MATSUO K, Machida H, Takiuchi T, Garcia-Sayre J, et al
    Prognosis of women with apparent stage I endometrial cancer who had supracervical hysterectomy.
    Gynecol Oncol. 2017 Feb 16. pii: S0090-8258(17)30115.
    PubMed     Text format     Abstract available


  78. ROSS J, Braswell KV, da Silva LM, Mujica F, et al
    Unraveling the etiology of ovarian cancer racial disparity in the deep south: Is it nature or nurture?
    Gynecol Oncol. 2017 Feb 16. pii: S0090-8258(17)30146.
    PubMed     Text format     Abstract available


  79. MATSUO K, Omatsu K, Ross MS, Johnson MS, et al
    Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma.
    Gynecol Oncol. 2017 Feb 16. pii: S0090-8258(17)30080.
    PubMed     Text format     Abstract available


  80. BURGHAUS S, Fasching PA, Haberle L, Rubner M, et al
    Genetic risk factors for ovarian cancer and their role for endometriosis risk.
    Gynecol Oncol. 2017 Feb 14. pii: S0090-8258(17)30143.
    PubMed     Text format     Abstract available


  81. KOHLER RS, Kettelhack H, Knipprath-Meszaros AM, Fedier A, et al
    MELK expression in ovarian cancer correlates with poor outcome and its inhibition by OTSSP167 abrogates proliferation and viability of ovarian cancer cells.
    Gynecol Oncol. 2017 Feb 14. pii: S0090-8258(17)30128.
    PubMed     Text format     Abstract available


  82. SEAGLE BL, Sobecki-Rausch J, Strohl AE, Shilpi A, et al
    Prognosis and treatment of uterine leiomyosarcoma: A National Cancer Database study.
    Gynecol Oncol. 2017 Feb 14. pii: S0090-8258(17)30123.
    PubMed     Text format     Abstract available


  83. SUIDAN RS, Ramirez PT, Sarasohn DM, Teitcher JB, et al
    A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer.
    Gynecol Oncol. 2017 Feb 13. pii: S0090-8258(17)30132.
    PubMed     Text format     Abstract available


  84. RICCI S, Stone RL, Fader AN
    Uterine leiomyosarcoma: Epidemiology, contemporary treatment strategies and the impact of uterine morcellation.
    Gynecol Oncol. 2017 Feb 13. pii: S0090-8258(17)30131.
    PubMed     Text format     Abstract available


  85. SKALLEBERG J, Solheim O, Fossa SD, Smastuen MC, et al
    Long-term ototoxicity in women after cisplatin treatment for ovarian germ cell cancer.
    Gynecol Oncol. 2017 Feb 12. pii: S0090-8258(17)30117.
    PubMed     Text format     Abstract available


  86. CARVAJAL-HAUSDORF DE, Schalper KA, Bai Y, Black J, et al
    Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance.
    Gynecol Oncol. 2017 Feb 11. pii: S0090-8258(17)30079.
    PubMed     Text format     Abstract available


  87. SEAGLE BL, Shahabi S
    Cost-effectiveness analysis of dose-dense versus standard intravenous chemotherapy for ovarian cancer: An economic analysis of results from the Gynecologic Oncology Group protocol 262 randomized controlled trial.
    Gynecol Oncol. 2017 Feb 10. pii: S0090-8258(17)30125.
    PubMed     Text format     Abstract available


  88. LAIRSON DR, Fu S, Chan W, Xu L, et al
    Mean direct medical care costs associated with cervical cancer for commercially insured patients in Texas.
    Gynecol Oncol. 2017 Feb 10. pii: S0090-8258(17)30122.
    PubMed     Text format     Abstract available


  89. GEPPERT B, Lonnerfors C, Bollino M, Arechvo A, et al
    A study on uterine lymphatic anatomy for standardization of pelvic sentinel lymph node detection in endometrial cancer.
    Gynecol Oncol. 2017 Feb 10. pii: S0090-8258(17)30130.
    PubMed     Text format     Abstract available


  90. MAI PL, Piedmonte M, Han PK, Moser RP, et al
    Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2017 Feb 10. pii: S0090-8258(17)30119.
    PubMed     Text format     Abstract available


  91. LEFRINGHOUSE JR, Elder JW, Baldwin LA, Miller RW, et al
    Prospective validation of an intraoperative algorithm to guide surgical staging in early endometrial cancer.
    Gynecol Oncol. 2017 Feb 9. pii: S0090-8258(17)30076.
    PubMed     Text format     Abstract available


  92. SALVO G, Ramirez PT, Levenback CF, Munsell MF, et al
    Sensitivity and negative predictive value for sentinel lymph node biopsy in women with early-stage cervical cancer.
    Gynecol Oncol. 2017 Feb 7. pii: S0090-8258(17)30116.
    PubMed     Text format     Abstract available


  93. OBERMAIR A, Simunovic M, Isenring L, Janda M, et al
    Nutrition interventions in patients with gynecological cancers requiring surgery.
    Gynecol Oncol. 2017 Feb 4. pii: S0090-8258(17)30072.
    PubMed     Text format     Abstract available


  94. KENTWELL M, Dow E, Antill Y, Wrede CD, et al
    Mainstreaming cancer genetics: A model integrating germline BRCA testing into routine ovarian cancer clinics.
    Gynecol Oncol. 2017 Feb 3. pii: S0090-8258(17)30074.
    PubMed     Text format     Abstract available


  95. SMITH JA, Mathew L, Burney M, Nyshadham P, et al
    Corrigendum to 'Equivalency challenge: evaluation of Lipodox(R) as the generic equivalent for Doxil(R) in a human ovarian cancer orthotropic mouse model' [Gynecol. Oncol. 141 (2016) 357-363].
    Gynecol Oncol. 2017;144:448.
    PubMed     Text format    


  96. WESTIN SN, Coleman RL
    Individualized Medicine in Ovarian Cancer: Are We There Yet?
    Gynecol Oncol. 2017;144:229-231.
    PubMed     Text format    


  97. COHN DE, Backes FJ, Wallbillich JJ, Bixel K, et al
    Recurrent low grade serous ovarian cancer in a 20 year old woman: A case from the Ohio State University College of Medicine.
    Gynecol Oncol. 2017 Feb 1. pii: S0090-8258(17)30067.
    PubMed     Text format     Abstract available


  98. BREGAR AJ, Alejandro Rauh-Hain J, Spencer R, Clemmer JT, et al
    Disparities in receipt of care for high-grade endometrial cancer: A National Cancer Data Base analysis.
    Gynecol Oncol. 2017 Feb 1. pii: S0090-8258(17)30068.
    PubMed     Text format     Abstract available


  99. EOH KJ, Park JS, Park HS, Lee ST, et al
    BRCA1 and BRCA2 mutation predictions using the BRCAPRO and Myriad models in Korean ovarian cancer patients.
    Gynecol Oncol. 2017 Feb 1. pii: S0090-8258(17)30070.
    PubMed     Text format     Abstract available


    January 2017
  100. WALLACE S, Kumar A, Mc Gree M, Weaver A, et al
    Efforts at maximal cytoreduction improve survival in ovarian cancer patients, even when complete gross resection is not feasible.
    Gynecol Oncol. 2017 Jan 31. pii: S0090-8258(17)30073.
    PubMed     Text format     Abstract available


  101. CHANAKIRA A, Westmark PR, Ong IM, Sheehan JP, et al
    Tissue factor-factor VIIa complex triggers protease activated receptor 2-dependent growth factor release and migration in ovarian cancer.
    Gynecol Oncol. 2017 Jan 29. pii: S0090-8258(17)30066.
    PubMed     Text format     Abstract available


  102. DALTON HJ, Fleming ND, Sun CC, Bhosale P, et al
    Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience.
    Gynecol Oncol. 2017 Jan 27. pii: S0090-8258(17)30071.
    PubMed     Text format     Abstract available


  103. LIN LH, Maesta I, Braga A, Sun SY, et al
    Multiple pregnancies with complete mole and coexisting normal fetus in North and South America: A retrospective multicenter cohort and literature review.
    Gynecol Oncol. 2017 Jan 26. pii: S0090-8258(17)30065.
    PubMed     Text format     Abstract available


  104. MATSUO K, Machida H, Takiuchi T, Grubbs BH, et al
    Role of hysterectomy and lymphadenectomy in the management of early-stage borderline ovarian tumors.
    Gynecol Oncol. 2017 Jan 26. pii: S0090-8258(17)30063.
    PubMed     Text format     Abstract available


  105. SUIDAN RS, He W, Sun CC, Zhao H, et al
    Impact of body mass index and operative approach on surgical morbidity and costs in women with endometrial carcinoma and hyperplasia.
    Gynecol Oncol. 2017 Jan 25. pii: S0090-8258(17)30069.
    PubMed     Text format     Abstract available


  106. HO CK, Kornaga EN, Klimowicz AC, Enwere EK, et al
    Expression of DNA damage response proteins in cervical cancer patients treated with radical chemoradiotherapy.
    Gynecol Oncol. 2017 Jan 25. pii: S0090-8258(16)31689.
    PubMed     Text format     Abstract available


  107. COX BAUER CM, Greer DM, Kram JJ, Kamelle SA, et al
    Corrigendum to 'Tumor diameter as a predictor of lymphatic dissemination in endometrioid endometrial cancer' [Gynecol. Oncol. 141 (2016) 199-205].
    Gynecol Oncol. 2017 Jan 25. pii: S0090-8258(16)31618.
    PubMed     Text format    


  108. ALETTI GD, Garbi A, Messori P, Achilarre MT, et al
    Multidisciplinary approach in the management of advanced ovarian cancer patients: A personalized approach. Results from a specialized ovarian cancer unit.
    Gynecol Oncol. 2017 Jan 20. pii: S0090-8258(17)30061.
    PubMed     Text format     Abstract available


  109. WINTERHOFF BJ, Maile M, Mitra AK, Sebe A, et al
    Single cell sequencing reveals heterogeneity within ovarian cancer epithelium and cancer associated stromal cells.
    Gynecol Oncol. 2017 Jan 19. pii: S0090-8258(17)30059.
    PubMed     Text format     Abstract available


  110. REISS KA, Herman JM, Armstrong D, Zahurak M, et al
    A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian
    Gynecol Oncol. 2017 Jan 18. pii: S0090-8258(17)30060.
    PubMed     Text format     Abstract available


  111. MACHIDA H, Nathenson MJ, Takiuchi T, Adams CL, et al
    Significance of lymph node metastasis on survival of women with uterine adenosarcoma.
    Gynecol Oncol. 2017 Jan 18. pii: S0090-8258(17)30050.
    PubMed     Text format     Abstract available


  112. LEE YJ, Kim DY, Lee SW, Park JY, et al
    A postoperative scoring system for distant recurrence in node-positive cervical cancer patients after radical hysterectomy and pelvic lymph node dissection with para-aortic lymph node sampling or dissection.
    Gynecol Oncol. 2017 Jan 17. pii: S0090-8258(17)30001.
    PubMed     Text format     Abstract available


  113. RASMUSSEN EL, Hannibal CG, Dehlendorff C, Baandrup L, et al
    Parity, infertility, oral contraceptives, and hormone replacement therapy and the risk of ovarian serous borderline tumors: A nationwide case-control study.
    Gynecol Oncol. 2017 Jan 17. pii: S0090-8258(17)30039.
    PubMed     Text format     Abstract available


  114. HOW J, Gauthier C, Abitbol J, Lau S, et al
    Impact of sentinel lymph node mapping on recurrence patterns in endometrial cancer.
    Gynecol Oncol. 2017 Jan 16. pii: S0090-8258(17)30057.
    PubMed     Text format     Abstract available


  115. HALTIA UM, Andersson N, Yadav B, Farkkila A, et al
    Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells.
    Gynecol Oncol. 2017 Jan 16. pii: S0090-8258(16)31681.
    PubMed     Text format     Abstract available


  116. ALEXANDRE E, Sebastien G, Renaud M, Enrica B, et al
    Outcome of early stage cervical cancer patients treated according to a radiosurgical approach: Clinical results and prognostic factors.
    Gynecol Oncol. 2017 Jan 14. pii: S0090-8258(16)31690.
    PubMed     Text format     Abstract available


  117. SWAILES AL, Gockley A, Phaeton R, Kesterson JP, et al
    The Wertheim hysterectomy: Development, modifications, and impact in the present day.
    Gynecol Oncol. 2017 Jan 13. pii: S0090-8258(17)30049.
    PubMed     Text format     Abstract available


  118. LIAO JB, Swensen RE, Ovenell KJ, Hitchcock-Bernhardt KM, et al
    Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer.
    Gynecol Oncol. 2017 Jan 12. pii: S0090-8258(17)30046.
    PubMed     Text format     Abstract available


  119. VON GRUENIGEN VE, Huang HQ, Beumer JH, Lankes HA, et al
    Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2017 Jan 12. pii: S0090-8258(16)31602.
    PubMed     Text format     Abstract available


  120. SEAGLE BL, Kanis M, Kocherginsky M, Strauss JB, et al
    Stage I uterine carcinosarcoma: Matched cohort analyses for lymphadenectomy, chemotherapy, and brachytherapy.
    Gynecol Oncol. 2017 Jan 12. pii: S0090-8258(17)30048.
    PubMed     Text format     Abstract available


  121. GILLEN J, Gunderson C, Greenwade M, Rowland M, et al
    Contribution of age to clinical trial enrollment and tolerance with ovarian cancer.
    Gynecol Oncol. 2017 Jan 10. pii: S0090-8258(16)31687.
    PubMed     Text format     Abstract available


  122. BEDELL S, Manders D, Kehoe S, Lea J, et al
    The opinions and practices of providers toward the sexual issues of cervical cancer patients undergoing treatment.
    Gynecol Oncol. 2017 Jan 9. pii: S0090-8258(16)31686.
    PubMed     Text format     Abstract available


  123. ISLAM MM, Banerjee T, Packard CZ, Kotian S, et al
    HDAC10 as a potential therapeutic target in ovarian cancer.
    Gynecol Oncol. 2017 Jan 7. pii: S0090-8258(17)30047.
    PubMed     Text format     Abstract available


  124. TOZZI R, Hardern K, Gubbala K, Garruto Campanile R, et al
    En-bloc resection of the pelvis (EnBRP) in patients with stage IIIC-IV ovarian cancer: A 10 steps standardised technique. Surgical and survival outcomes of primary vs. interval surgery.
    Gynecol Oncol. 2017 Jan 7. pii: S0090-8258(16)31683.
    PubMed     Text format     Abstract available


  125. TUOMI T, Pasanen A, Leminen A, Butzow R, et al
    Prediction of lymphatic dissemination in endometrioid endometrial cancer: Comparison of three risk-stratification models in a single-institution cohort.
    Gynecol Oncol. 2017 Jan 6. pii: S0090-8258(17)30041.
    PubMed     Text format     Abstract available


  126. GOTTLIEB CE, Mills AM, Cross JV, Ring KL, et al
    Tumor-associated macrophage expression of PD-L1 in implants of high grade serous ovarian carcinoma: A comparison of matched primary and metastatic tumors.
    Gynecol Oncol. 2017 Jan 5. pii: S0090-8258(16)31685.
    PubMed     Text format     Abstract available


  127. RYAN NA, Evans DG, Green K, Crosbie EJ, et al
    Pathological features and clinical behavior of Lynch syndrome-associated ovarian cancer.
    Gynecol Oncol. 2017 Jan 5. pii: S0090-8258(17)30042.
    PubMed     Text format     Abstract available


  128. DIZON DS
    Neoadjuvant chemotherapy for newly diagnosed ovarian cancer: It's all about selection.
    Gynecol Oncol. 2017 Jan 3. pii: S0090-8258(16)31684.
    PubMed     Text format    


  129. PIERCE SR, Stine JE, Gehrig PA, Havrilesky LJ, et al
    Prior breast cancer and tamoxifen exposure does not influence outcomes in women with uterine papillary serous carcinoma.
    Gynecol Oncol. 2017 Jan 3. pii: S0090-8258(16)31688.
    PubMed     Text format     Abstract available


  130. SPREAFICO A, Oza AM, Clarke BA, Mackay HJ, et al
    Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC).
    Gynecol Oncol. 2017 Jan 3. pii: S0090-8258(16)31620.
    PubMed     Text format     Abstract available


  131. ANGIOLO G, Silvestro C, Giovanni A
    Neuroendrocrine tumors of the uterine cervix: A therapeutic challenge for gynecologic oncologists.
    Gynecol Oncol. 2017 Jan 2. pii: S0090-8258(16)31621.
    PubMed     Text format     Abstract available


  132. FRUMOVITZ M
    Sentinel Lymph Node Biopsy for Cervical Cancer Patients - What's It Gonna Take?
    Gynecol Oncol. 2017;144:3-4.
    PubMed     Text format    


  133. KARLAN BY
    Gynecologic Oncology 2017 Update: New Features and Expanded Scope.
    Gynecol Oncol. 2017;144:1-2.
    PubMed     Text format    


  134. HYMAN DM, Sill MW, Lankes HA, Piekarz R, et al
    A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D.
    Gynecol Oncol. 2017;144:96-100.
    PubMed     Text format     Abstract available


  135. BERGAMINI A, Pisano C, Di Napoli M, Arenare L, et al
    Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin.
    Gynecol Oncol. 2017;144:72-76.
    PubMed     Text format     Abstract available


  136. KIM M, Suh DH, Yang EJ, Lim MC, et al
    Identifying risk factors for occult lower extremity lymphedema using computed tomography in patients undergoing lymphadenectomy for gynecologic cancers.
    Gynecol Oncol. 2017;144:153-158.
    PubMed     Text format     Abstract available


    December 2016
  137. KESSOUS R, Laskov I, Abitbol J, Bitharas J, et al
    Clinical outcome of neoadjuvant chemotherapy for advanced ovarian cancer.
    Gynecol Oncol. 2016 Dec 29. pii: S0090-8258(16)31679.
    PubMed     Text format     Abstract available


  138. PIULATS JM, Guerra E, Gil-Martin M, Roman-Canal B, et al
    Molecular approaches for classifying endometrial carcinoma.
    Gynecol Oncol. 2016 Dec 28. pii: S0090-8258(16)31680.
    PubMed     Text format     Abstract available


  139. BENOIT MF, Ma JF, Upperman BA
    Comparison of 2015 Medicare relative value units for gender-specific procedures: Gynecologic and gynecologic-oncologic versus urologic CPT coding. Has time healed gender-worth?
    Gynecol Oncol. 2016 Dec 23. pii: S0090-8258(16)31624.
    PubMed     Text format     Abstract available


  140. NAROD S, Sopik V
    Neoadjuvant chemotherapy for advanced-stage ovarian cancer: Are the ASCO and SGO recommendations warranted?
    Gynecol Oncol. 2016 Dec 22. pii: S0090-8258(16)31615.
    PubMed     Text format    


  141. MATSUO K, Machida H, Ragab OM, Takiuchi T, et al
    Extent of pelvic lymphadenectomy and use of adjuvant vaginal brachytherapy for early-stage endometrial cancer.
    Gynecol Oncol. 2016 Dec 22. pii: S0090-8258(16)31670.
    PubMed     Text format     Abstract available


  142. CHAN JL, Wang ET
    Oncofertility for women with gynecologic malignancies.
    Gynecol Oncol. 2016 Dec 21. pii: S0090-8258(16)31671.
    PubMed     Text format     Abstract available


  143. SUAREZ AA, Felix AS, Cohn DE
    Bokhman Redux: Endometrial cancer "types" in the 21st century.
    Gynecol Oncol. 2016 Dec 16. pii: S0090-8258(16)31668.
    PubMed     Text format     Abstract available


  144. LEFKOWITS C, Duska L
    Opioid Use in Gynecologic Oncology; Balancing Efficacy, Accessibility and Safety: An SGO Clinical Practice Statement.
    Gynecol Oncol. 2016 Dec 14. pii: S0090-8258(16)31571.
    PubMed     Text format    


  145. DOLL KM, Pinheiro LC, Reeve BB
    Pre-diagnosis health-related quality of life, surgery, and survival in women with advanced epithelial ovarian cancer: A SEER-MHOS study.
    Gynecol Oncol. 2016 Dec 14. pii: S0090-8258(16)31623.
    PubMed     Text format     Abstract available


  146. RUBERG JL, Helm CW, Felleman BI, Helm JE, et al
    Is attendance at an ovarian cancer screening clinic a worry-reducing event? Findings from pre- to post-screening.
    Gynecol Oncol. 2016 Dec 13. pii: S0090-8258(16)31616.
    PubMed     Text format     Abstract available


  147. PRENDERGAST EN, Holzapfel M, Mueller JJ, Leitao MM Jr, et al
    Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma - A multi-institutional cohort.
    Gynecol Oncol. 2016 Dec 12. pii: S0090-8258(16)31622.
    PubMed     Text format     Abstract available


  148. MARU Y, Tanaka N, Ohira M, Itami M, et al
    Identification of novel mutations in Japanese ovarian clear cell carcinoma patients using optimized targeted NGS for clinical diagnosis.
    Gynecol Oncol. 2016 Dec 8. pii: S0090-8258(16)31614.
    PubMed     Text format     Abstract available


  149. RZEPECKA IK, Szafron LM, Stys A, Felisiak-Golabek A, et al
    Prognosis of patients with BRCA1-associated ovarian carcinomas depends on TP53 accumulation status in tumor cells.
    Gynecol Oncol. 2016 Dec 7. pii: S0090-8258(16)31597.
    PubMed     Text format     Abstract available


  150. MATZ M, Coleman MP, Sant M, Chirlaque MD, et al
    The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2).
    Gynecol Oncol. 2016 Dec 5. pii: S0090-8258(16)31497.
    PubMed     Text format     Abstract available


  151. MUSA F, Pothuri B, Blank SV, Ling HT, et al
    Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer.
    Gynecol Oncol. 2016 Dec 5. pii: S0090-8258(16)31612.
    PubMed     Text format     Abstract available


  152. MATSUO K, Ross MS, Bush SH, Yunokawa M, et al
    Tumor characteristics and survival outcomes of women with tamoxifen-related uterine carcinosarcoma.
    Gynecol Oncol. 2016 Dec 5. pii: S0090-8258(16)31611.
    PubMed     Text format     Abstract available


  153. KALOGERA E, Nitschmann CC, Dowdy SC, Cliby WA, et al
    A prospective algorithm to reduce anastomotic leaks after rectosigmoid resection for gynecologic malignancies.
    Gynecol Oncol. 2016 Dec 2. pii: S0090-8258(16)31601.
    PubMed     Text format     Abstract available


  154. MATZ M, Coleman MP, Carreira H, Salmeron D, et al
    Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2).
    Gynecol Oncol. 2016 Dec 2. pii: S0090-8258(16)31575.
    PubMed     Text format     Abstract available


  155. DOTTINO JA, Lu KH
    Towards value-based universal Lynch syndrome identification in endometrial cancer patients.
    Gynecol Oncol. 2016;143:451-452.
    PubMed     Text format    


  156. GILL SE, McGree ME, Weaver AL, Cliby WA, et al
    Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
    Gynecol Oncol. 2016 Dec 1. pii: S0090-8258(16)31577.
    PubMed     Text format     Abstract available


    November 2016
  157. ADAMBEKOV S, Goughnour SL, Mansuria S, Donnellan N, et al
    Patient and provider factors associated with endometrial Pipelle sampling failure.
    Gynecol Oncol. 2016 Nov 29. pii: S0090-8258(16)31610.
    PubMed     Text format     Abstract available


  158. SEAGLE BL, Butler SK, Strohl AE, Nieves-Neira W, et al
    Chemotherapy delay after primary debulking surgery for ovarian cancer.
    Gynecol Oncol. 2016 Nov 28. pii: S0090-8258(16)31578.
    PubMed     Text format     Abstract available


  159. SAPIENZA LG, Gomes MJ, Calsavara VF, Leitao MM Jr, et al
    Does para-aortic irradiation reduce the risk of distant metastasis in advanced cervical cancer? A systematic review and meta-analysis of randomized clinical trials.
    Gynecol Oncol. 2016 Nov 28. pii: S0090-8258(16)31613.
    PubMed     Text format     Abstract available


  160. KUJI S, Watanabe R, Sato Y, Iwata T, et al
    A new marker, insulinoma-associated protein 1 (INSM1), for high-grade neuroendocrine carcinoma of the uterine cervix: Analysis of 37 cases.
    Gynecol Oncol. 2016 Nov 28. pii: S0090-8258(16)31576.
    PubMed     Text format     Abstract available


  161. NASIOUDIS D, Chapman-Davis E, Witkin SS, Holcomb K, et al
    Prognostic significance of lymphadenectomy and prevalence of lymph node metastasis in clinically-apparent stage I endometrioid and mucinous ovarian carcinoma.
    Gynecol Oncol. 2016 Nov 28. pii: S0090-8258(16)31607.
    PubMed     Text format     Abstract available


  162. MILLER RE, Ledermann JA
    The European Society for Medical Oncology 2016 Congress: Highlights and summary of selected abstracts in gynecologic cancers.
    Gynecol Oncol. 2016 Nov 27. pii: S0090-8258(16)31609.
    PubMed     Text format    


  163. ROSS GREEN W, Hathout L, Khan AJ, Elshaikh MA, et al
    Revisiting Milan cervical cancer study: Do the original findings hold in the era of chemotherapy?
    Gynecol Oncol. 2016 Nov 26. pii: S0090-8258(16)31603.
    PubMed     Text format     Abstract available


  164. SULLIVAN SA, Clark LH, Staley AS, Tran AQ, et al
    Association between timing of cervical excision procedure to minimally invasive hysterectomy and surgical complications.
    Gynecol Oncol. 2016 Nov 25. pii: S0090-8258(16)31606.
    PubMed     Text format     Abstract available


  165. BEACHLER DC, Tota JE, Silver MI, Kreimer AR, et al
    Trends in cervical cancer incidence in younger US women from 2000 to 2013.
    Gynecol Oncol. 2016 Nov 25. pii: S0090-8258(16)31600.
    PubMed     Text format     Abstract available


  166. BELLONE S, Bignotti E, Lonardi S, Ferrari F, et al
    Polymerase epsilon (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro.
    Gynecol Oncol. 2016 Nov 25. pii: S0090-8258(16)31579.
    PubMed     Text format     Abstract available


  167. KONG TW, Lee JD, Son JH, Paek J, et al
    Corrigendum to 'Treatment outcomes in patients with FIGO stage IB-IIA cervical cancer and a focally disrupted cervical stromal ring on magnetic resonance imaging: A propensity score matching study' [Gynecol. Oncol. 143 (2016) 77-82].
    Gynecol Oncol. 2016 Nov 24. pii: S0090-8258(16)31522.
    PubMed     Text format    


  168. BARBER EL, Clarke-Pearson DL
    Prevention of venous thromboembolism in gynecologic oncology surgery.
    Gynecol Oncol. 2016 Nov 24. pii: S0090-8258(16)31605.
    PubMed     Text format     Abstract available


  169. KARNEZIS AN, Cho KR
    Of mice and women - Non-ovarian origins of "ovarian" cancer.
    Gynecol Oncol. 2016 Nov 24. pii: S0090-8258(16)31608.
    PubMed     Text format    


  170. DE DECKER K, Speth S, Ter Brugge HG, Bart J, et al
    Staging procedures in patients with mucinous borderline tumors of the ovary do not reveal peritoneal or omental disease.
    Gynecol Oncol. 2016 Nov 23. pii: S0090-8258(16)31604.
    PubMed     Text format     Abstract available


  171. CHENG A, Li M, Kanis MJ, Xu Y, et al
    Is it necessary to perform routine appendectomy for mucinous ovarian neoplasms? A retrospective study and meta-analysis.
    Gynecol Oncol. 2016 Nov 23. pii: S0090-8258(16)31518.
    PubMed     Text format     Abstract available


  172. MANNE SL, Virtue SM, Ozga M, Kashy D, et al
    A comparison of two psychological interventions for newly-diagnosed gynecological cancer patients.
    Gynecol Oncol. 2016 Nov 22. pii: S0090-8258(16)31581.
    PubMed     Text format     Abstract available


  173. OSBORN V, Schwartz D, Lee YC, Lee A, et al
    Patterns of care of IMRT usage in postoperative management of uterine cancer.
    Gynecol Oncol. 2016 Nov 22. pii: S0090-8258(16)31573.
    PubMed     Text format     Abstract available


  174. SMITH B, McCann GA, Phillips G, Backes FJ, et al
    Less radical surgery for early-stage cervical cancer: Can conization specimens help identify patients at low risk for parametrial involvement?
    Gynecol Oncol. 2016 Nov 21. pii: S0090-8258(16)31598.
    PubMed     Text format     Abstract available


  175. TAYLOR KN, McHale MT, Saenz CC, Plaxe SC, et al
    Diagnosis and treatment of Clostridium difficile (C. diff) colitis: Review of the literature and a perspective in gynecologic oncology.
    Gynecol Oncol. 2016 Nov 19. pii: S0090-8258(16)31580.
    PubMed     Text format     Abstract available


  176. SORIO R, Roemer-Becuwe C, Hilpert F, Gibbs E, et al
    Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial.
    Gynecol Oncol. 2016 Nov 18. pii: S0090-8258(16)31562.
    PubMed     Text format     Abstract available


  177. HALTIA UM, Hallamaa M, Tapper J, Hynninen J, et al
    Roles of human epididymis protein 4, carbohydrate antigen 125, inhibin B and anti-Mullerian hormone in the differential diagnosis and follow-up of ovarian granulosa cell tumors.
    Gynecol Oncol. 2016 Nov 18. pii: S0090-8258(16)31574.
    PubMed     Text format     Abstract available


  178. HEITZ F, Hengsbach A, Harter P, Traut A, et al
    Intake of selective beta blockers has no impact on survival in patients with epithelial ovarian cancer.
    Gynecol Oncol. 2016 Nov 16. pii: S0090-8258(16)31567.
    PubMed     Text format     Abstract available


  179. SHIM SH, Kim DY, Lee SJ, Kim SN, et al
    Prediction model for para-aortic lymph node metastasis in patients with locally advanced cervical cancer.
    Gynecol Oncol. 2016 Nov 14. pii: S0090-8258(16)31568.
    PubMed     Text format     Abstract available


  180. DEL CARMEN MG, Rice LW
    International Gynecologic Cancer Society (IGCS) 2016: Meeting report.
    Gynecol Oncol. 2016 Nov 12. pii: S0090-8258(16)31572.
    PubMed     Text format    


  181. CORDEIRO VIDAL G, Babin G, Querleu D, Guyon F, et al
    Primary debulking surgery of the upper abdomen and the diaphragm, with a plasma device surgery system, for advanced ovarian cancer.
    Gynecol Oncol. 2016 Nov 8. pii: S0090-8258(16)31507.
    PubMed     Text format     Abstract available


  182. LI Y, Zhang HL, Kang S, Zhou RM, et al
    The effect of polymorphisms in PD-1 gene on the risk of epithelial ovarian cancer and patients' outcomes.
    Gynecol Oncol. 2016 Nov 8. pii: S0090-8258(16)31566.
    PubMed     Text format     Abstract available


  183. THOMAS ED, Nugent EK, MacAllister MC, Moxley KM, et al
    Effectiveness of cyanoacrylate microbial sealant in the reduction of surgical site infection in gynecologic oncology procedures: A phase III single institution prospective randomized trial.
    Gynecol Oncol. 2016 Nov 8. pii: S0090-8258(16)31564.
    PubMed     Text format     Abstract available


  184. HANNIBAL CG, Vang R, Junge J, Frederiksen K, et al
    A nationwide study of ovarian serous borderline tumors in Denmark 1978-2002. Risk of recurrence, and development of ovarian serous carcinoma.
    Gynecol Oncol. 2016 Nov 8. pii: S0090-8258(16)31563.
    PubMed     Text format     Abstract available


  185. MARCHETTI C, Kristeleit R, McCormack M, Mould T, et al
    Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review.
    Gynecol Oncol. 2016 Nov 5. pii: S0090-8258(16)31520.
    PubMed     Text format     Abstract available


  186. WONG AT, Rineer J, Schwartz D, Weiner J, et al
    Patterns of adjuvant radiation usage and survival outcomes for stage I endometrial carcinoma in a large hospital-based cohort.
    Gynecol Oncol. 2016 Nov 4. pii: S0090-8258(16)31521.
    PubMed     Text format     Abstract available


  187. RASPAGLIESI F, Maltese G, Bogani G, Fuca G, et al
    Morcellation worsens survival outcomes in patients with undiagnosed uterine leiomyosarcomas: A retrospective MITO group study.
    Gynecol Oncol. 2016 Nov 4. pii: S0090-8258(16)31519.
    PubMed     Text format     Abstract available


  188. DAHM-KAHLER P, Borgfeldt C, Holmberg E, Staf C, et al
    Population-based study of survival for women with serous cancer of the ovary, fallopian tube, peritoneum or undesignated origin - on behalf of the Swedish gynecological cancer group (SweGCG).
    Gynecol Oncol. 2016 Nov 3. pii: S0090-8258(16)31516.
    PubMed     Text format     Abstract available


  189. MILLER CR, Chappell NP, Sledge C, Leath CA 3rd, et al
    Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174?
    Gynecol Oncol. 2016 Nov 2. pii: S0090-8258(16)31515.
    PubMed     Text format     Abstract available


    October 2016
  190. FALLON J, Park SJ, Yang L, Veruttipong D, et al
    Long term results from a prospective database on high dose rate (HDR) interstitial brachytherapy for primary cervical carcinoma.
    Gynecol Oncol. 2016 Oct 29. pii: S0090-8258(16)31496.
    PubMed     Text format     Abstract available


  191. DESALE MG, Tanner EJ 3rd, Sinno AK, Angarita AA, et al
    Perioperative fluid status and surgical outcomes in patients undergoing cytoreductive surgery for advanced epithelial ovarian cancer.
    Gynecol Oncol. 2016 Oct 28. pii: S0090-8258(16)31501.
    PubMed     Text format     Abstract available


  192. MCCOURT CK, Deng W, Dizon DS, Lankes HA, et al
    A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2016 Oct 28. pii: S0090-8258(16)31502.
    PubMed     Text format     Abstract available


  193. GUPTA V, McGunigal M, Prasad-Hayes M, Kalir T, et al
    Adjuvant radiation therapy is associated with improved overall survival in high-intermediate risk stage I endometrial cancer: A national cancer data base analysis.
    Gynecol Oncol. 2016 Oct 25. pii: S0090-8258(16)31500.
    PubMed     Text format     Abstract available


  194. HOROWITZ NS, Goldstein DP, Berkowitz RS
    Placental site trophoblastic tumors and epithelioid trophoblastic tumors: Biology, natural history, and treatment modalities.
    Gynecol Oncol. 2016 Oct 24. pii: S0090-8258(16)31505.
    PubMed     Text format     Abstract available


  195. GOVERDE A, Spaander MC, van Doorn HC, Dubbink HJ, et al
    Cost-effectiveness of routine screening for Lynch syndrome in endometrial cancer patients up to 70years of age.
    Gynecol Oncol. 2016 Oct 24. pii: S0090-8258(16)31480.
    PubMed     Text format     Abstract available


  196. BENDIFALLAH S, Ouldamer L, Lavoue V, Canlorbe G, et al
    Patterns of recurrence and outcomes in surgically treated women with endometrial cancer according to ESMO-ESGO-ESTRO Consensus Conference risk groups: Results from the FRANCOGYN study Group.
    Gynecol Oncol. 2016 Oct 24. pii: S0090-8258(16)31503.
    PubMed     Text format     Abstract available


  197. KIM JY, Byun SJ, Kim YS, Nam JH, et al
    Disease courses in patients with residual tumor following concurrent chemoradiotherapy for locally advanced cervical cancer.
    Gynecol Oncol. 2016 Oct 24. pii: S0090-8258(16)31509.
    PubMed     Text format     Abstract available


  198. HAQUE W, Verma V, Fakhreddine M, Hatch S, et al
    Addition of chemotherapy to definitive radiotherapy for IB1 and IIA1 cervical cancer: Analysis of the National Cancer Data Base.
    Gynecol Oncol. 2016 Oct 23. pii: S0090-8258(16)31510.
    PubMed     Text format     Abstract available


  199. HAGEN B, Valla M, Aune G, Ravlo M, et al
    Indocyanine green fluorescence imaging of lymph nodes during robotic-assisted laparoscopic operation for endometrial cancer. A prospective validation study using a sentinel lymph node surgical algorithm.
    Gynecol Oncol. 2016 Oct 21. pii: S0090-8258(16)31506.
    PubMed     Text format     Abstract available


  200. CHAN JK, Java JJ, Fuh K, Monk BJ, et al
    The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients - An analysis of NRG oncology/gynecologic oncology group trials.
    Gynecol Oncol. 2016 Oct 19. pii: S0090-8258(16)31421.
    PubMed     Text format     Abstract available


  201. LEE JY, Kim K, Lee YS, Kim HY, et al
    Treatment preferences of advanced ovarian cancer patients for adding bevacizumab to first-line therapy.
    Gynecol Oncol. 2016 Oct 19. pii: S0090-8258(16)31498.
    PubMed     Text format     Abstract available


  202. GUELI ALLETTI S, Petrillo M, Vizzielli G, Bottoni C, et al
    Minimally invasive versus standard laparotomic interval debulking surgery in ovarian neoplasm: A single-institution retrospective case-control study.
    Gynecol Oncol. 2016 Oct 18. pii: S0090-8258(16)31491.
    PubMed     Text format     Abstract available


  203. MAHMOUD O, Hathout L, Shaaban SG, Elshaikh MA, et al
    Can chemotherapy boost the survival benefit of adjuvant radiotherapy in early stage cervical cancer with intermediate risk factors? A population based study.
    Gynecol Oncol. 2016 Oct 18. pii: S0090-8258(16)31499.
    PubMed     Text format     Abstract available


  204. SEAGLE BL, Dayno M, Strohl AE, Graves S, et al
    Survival after pelvic exenteration for uterine malignancy: A National Cancer Data Base study.
    Gynecol Oncol. 2016 Oct 16. pii: S0090-8258(16)31495.
    PubMed     Text format     Abstract available


  205. WINTER MC, Tidy JA, Hills A, Ireson J, et al
    Risk adapted single-agent dactinomycin or carboplatin for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia.
    Gynecol Oncol. 2016 Oct 15. pii: S0090-8258(16)31435.
    PubMed     Text format     Abstract available


  206. CRAIG ER, Londono AI, Norian LA, Arend RC, et al
    Metabolic risk factors and mechanisms of disease in epithelial ovarian cancer: A review.
    Gynecol Oncol. 2016 Oct 14. pii: S0090-8258(16)31477.
    PubMed     Text format     Abstract available


  207. CAPRIGLIONE S, Plotti F, Montera R, Luvero D, et al
    Role of paroxetine in the management of hot flashes in gynecological cancer survivors: Results of the first randomized single-center controlled trial.
    Gynecol Oncol. 2016 Oct 14. pii: S0090-8258(16)31476.
    PubMed     Text format     Abstract available


  208. LEBLANC E, Narducci F, Bresson L, Hudry D, et al
    Fluorescence-assisted sentinel (SND) and pelvic node dissections by single-port transvaginal laparoscopic surgery, for the management of an endometrial carcinoma (EC) in an elderly obese patient.
    Gynecol Oncol. 2016 Oct 13. pii: S0090-8258(16)31482.
    PubMed     Text format     Abstract available


  209. BAI H, Cao D, Yuan F, Sha G, et al
    Prognostic value of endometriosis in patients with stage I ovarian clear cell carcinoma: Experiences at three academic institutions.
    Gynecol Oncol. 2016 Oct 13. pii: S0090-8258(16)31481.
    PubMed     Text format     Abstract available


  210. SOLIMAN PT, Zhang Q, Broaddus RR, Westin SN, et al
    Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study.
    Gynecol Oncol. 2016 Oct 13. pii: S0090-8258(16)31483.
    PubMed     Text format     Abstract available


  211. BROWN J, Naumann RW, Seckl MJ, Schink J, et al
    15years of progress in gestational trophoblastic disease: Scoring, standardization, and salvage.
    Gynecol Oncol. 2016 Oct 13. pii: S0090-8258(16)31356.
    PubMed     Text format     Abstract available


  212. KIM HS, Bristow RE, Chang SJ
    Total parietal peritonectomy with en bloc pelvic resection for advanced ovarian cancer with peritoneal carcinomatosis.
    Gynecol Oncol. 2016 Oct 13. pii: S0090-8258(16)31488.
    PubMed     Text format     Abstract available


  213. FADER AN, Java J, Tenney M, Ricci S, et al
    Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis.
    Gynecol Oncol. 2016 Oct 12. pii: S0090-8258(16)31490.
    PubMed     Text format     Abstract available


  214. FLEMING ND, Ramirez PT, Soliman PT, Schmeler KM, et al
    Quality of life after radical trachelectomy for early-stage cervical cancer: A 5-year prospective evaluation.
    Gynecol Oncol. 2016 Oct 11. pii: S0090-8258(16)31484.
    PubMed     Text format     Abstract available


  215. LENNOX GK, Covens A
    Can sentinel lymph node biopsy replace pelvic lymphadenectomy for early cervical cancer?
    Gynecol Oncol. 2016 Oct 11. pii: S0090-8258(16)31358.
    PubMed     Text format     Abstract available


  216. BRYK S, Farkkila A, Butzow R, Leminen A, et al
    Characteristics and outcome of recurrence in molecularly defined adult-type ovarian granulosa cell tumors.
    Gynecol Oncol. 2016 Oct 8. pii: S0090-8258(16)31473.
    PubMed     Text format     Abstract available


  217. GARCIA-SOTO AE, Java JJ, Nieves Neira W, Pearson JM, et al
    Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study.
    Gynecol Oncol. 2016 Oct 7. pii: S0090-8258(16)31474.
    PubMed     Text format     Abstract available


  218. LIAO Y, Deng Y, Liu J, Ye Z, et al
    MiR-760 overexpression promotes proliferation in ovarian cancer by downregulation of PHLPP2 expression.
    Gynecol Oncol. 2016 Oct 7. pii: S0090-8258(16)31410.
    PubMed     Text format     Abstract available


  219. BOOTHE D, Orton A, Odei B, Stoddard G, et al
    Corrigendum to "Chemoradiation versus chemotherapy or radiation alone in stage III endometrial cancer: Patterns of care and impact on overall survival" [Gynecol. Oncol. 141 (2016) 421-427].
    Gynecol Oncol. 2016 Oct 7. pii: S0090-8258(16)31429.
    PubMed     Text format    


  220. CHO LP, Manuel M, Catalano P, Lee L, et al
    Outcomes with volume-based dose specification in CT-planned high-dose-rate brachytherapy for stage I-II cervical carcinoma: A 10-year institutional experience.
    Gynecol Oncol. 2016 Oct 6. pii: S0090-8258(16)31423.
    PubMed     Text format     Abstract available


  221. BARRINGTON DA, Dilley SE, Landers EE, Thomas ED, et al
    Distance from a Comprehensive Cancer Center: A proxy for poor cervical cancer outcomes?
    Gynecol Oncol. 2016 Oct 6. pii: S0090-8258(16)31475.
    PubMed     Text format     Abstract available


  222. SHAFRIR AL, Rice MS, Gupta M, Terry KL, et al
    The association between reproductive and hormonal factors and ovarian cancer by estrogen-alpha and progesterone receptor status.
    Gynecol Oncol. 2016 Oct 5. pii: S0090-8258(16)31430.
    PubMed     Text format     Abstract available


  223. WRIGHT AA, Bohlke K, Armstrong DK, Bookman MA, et al
    Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.
    Gynecol Oncol. 2016;143:3-15.
    PubMed     Text format     Abstract available


  224. KAMRAVA M
    Intensity modulated radiation therapy for women with gynecologic cancers: this horse is also already out of the barn.
    Gynecol Oncol. 2016;143:1-2.
    PubMed     Text format    


    September 2016
  225. MISHKIN G, Minasian LM, Kohn EC, Noone AM, et al
    The generalizability of NCI-sponsored clinical trials accrual among women with gynecologic malignancies.
    Gynecol Oncol. 2016 Sep 30. pii: S0090-8258(16)31432.
    PubMed     Text format     Abstract available


  226. AL-NIAIMI A, Dickson EL, Albertin C, Karnowski J, et al
    The impact of perioperative beta blocker use on patient outcomes after primary cytoreductive surgery in high-grade epithelial ovarian carcinoma.
    Gynecol Oncol. 2016 Sep 29. pii: S0090-8258(16)31425.
    PubMed     Text format     Abstract available


  227. MUELLER JJ, Kelly A, Zhou Q, Iasonos A, et al
    Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center.
    Gynecol Oncol. 2016 Sep 28. pii: S0090-8258(16)31420.
    PubMed     Text format     Abstract available


  228. ROSE PG, Java JJ, Morgan MA, Alvarez-Secord A, et al
    Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2016 Sep 27. pii: S0090-8258(16)31368.
    PubMed     Text format     Abstract available


  229. ARMBRUSTER SD, Song J, Bradford A, Carmack CL, et al
    Sexual health of endometrial cancer survivors before and after a physical activity intervention: A retrospective cohort analysis.
    Gynecol Oncol. 2016 Sep 24. pii: S0090-8258(16)31422.
    PubMed     Text format     Abstract available


  230. OH J, Barve M, Matthews CM, Koon EC, et al
    Phase II study of Vigil(R) DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer.
    Gynecol Oncol. 2016 Sep 24. pii: S0090-8258(16)31424.
    PubMed     Text format     Abstract available


  231. WHITE ID, Sangha A, Lucas G, Wiseman T, et al
    Assessment of sexual difficulties associated with multi-modal treatment for cervical or endometrial cancer: A systematic review of measurement instruments.
    Gynecol Oncol. 2016 Sep 23. pii: S0090-8258(16)31359.
    PubMed     Text format     Abstract available


  232. FU Y, Biglia N, Wang Z, Shen Y, et al
    Long non-coding RNAs, ASAP1-IT1, FAM215A, and LINC00472, in epithelial ovarian cancer.
    Gynecol Oncol. 2016 Sep 23. pii: S0090-8258(16)31427.
    PubMed     Text format     Abstract available


  233. WILBUR MB, Mannschreck DB, Angarita AM, Matsuno RK, et al
    Unplanned 30-day hospital readmission as a quality measure in gynecologic oncology.
    Gynecol Oncol. 2016 Sep 21. pii: S0090-8258(16)31426.
    PubMed     Text format     Abstract available


  234. CAMPBELL G, Hagan T, Gilbertson-White S, Houze M, et al
    Cancer and treatment-related symptoms are associated with mobility disability in women with ovarian cancer: A cross-sectional study.
    Gynecol Oncol. 2016 Sep 18. pii: S0090-8258(16)31414.
    PubMed     Text format     Abstract available


  235. STECKLEIN SR, Jhingran A, Burzawa J, Ramalingam P, et al
    Patterns of recurrence and survival in neuroendocrine cervical cancer.
    Gynecol Oncol. 2016 Sep 16. pii: S0090-8258(16)31409.
    PubMed     Text format     Abstract available


  236. BRAGA A, Torres B, Burla M, Maesta I, et al
    Is chemotherapy necessary for patients with molar pregnancy and human chorionic gonadotropin serum levels raised but falling at 6months after uterine evacuation?
    Gynecol Oncol. 2016 Sep 15. pii: S0090-8258(16)31413.
    PubMed     Text format     Abstract available


  237. ROBIN TP, Amini A, Schefter TE, Behbakht K, et al
    Disparities in standard of care treatment and associated survival decrement in patients with locally advanced cervical cancer.
    Gynecol Oncol. 2016 Sep 15. pii: S0090-8258(16)31412.
    PubMed     Text format     Abstract available


  238. COWAN RA, Suidan RS, Andikyan V, Rezk YA, et al
    Electronic patient-reported outcomes from home in patients recovering from major gynecologic cancer surgery: A prospective study measuring symptoms and health-related quality of life.
    Gynecol Oncol. 2016 Sep 13. pii: S0090-8258(16)31362.
    PubMed     Text format     Abstract available


  239. KATO K, Nomura H, Nagashima M, Takeshima N, et al
    Secondary debulking surgery for isolated pelvic nodal recurrence requiring external iliac vein excision and reconstruction in a patient with ovarian cancer.
    Gynecol Oncol. 2016 Sep 11. pii: S0090-8258(16)31411.
    PubMed     Text format     Abstract available


  240. HOGEN L, Thomas G, Bernardini M, Bassiouny D, et al
    The effect of adjuvant radiation on survival in early stage clear cell ovarian carcinoma.
    Gynecol Oncol. 2016 Sep 9. pii: S0090-8258(16)31369.
    PubMed     Text format     Abstract available


  241. PINSKY PF, Yu K, Kramer BS, Black A, et al
    Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up.
    Gynecol Oncol. 2016 Sep 8. pii: S0090-8258(16)31361.
    PubMed     Text format     Abstract available


  242. SINGH S, Guetzko M, Resnick K
    Preoperative predictors of delay in initiation of adjuvant chemotherapy in patients undergoing primary debulking surgery for ovarian cancer.
    Gynecol Oncol. 2016 Sep 8. pii: S0090-8258(16)31367.
    PubMed     Text format     Abstract available


  243. ALHILLI MM, Becker MA, Weroha SJ, Flatten KS, et al
    In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.
    Gynecol Oncol. 2016 Sep 7. pii: S0090-8258(16)31355.
    PubMed     Text format     Abstract available


  244. MELAMED A, Hinchcliff EM, Clemmer JT, Bregar AJ, et al
    Trends in the use of neoadjuvant chemotherapy for advanced ovarian cancer in the United States.
    Gynecol Oncol. 2016 Sep 6. pii: S0090-8258(16)31365.
    PubMed     Text format     Abstract available


  245. NAKAYAMA M, Kobayashi H, Takahara T, Nishimura Y, et al
    A comparison of overall survival with 40 and 50mg/m2 pegylated liposomal doxorubicin treatment in patients with recurrent epithelial ovarian cancer: Propensity score-matched analysis of real-world data.
    Gynecol Oncol. 2016 Sep 6. pii: S0090-8258(16)31357.
    PubMed     Text format     Abstract available


  246. MANGILI G, Ottolina J, Cormio G, Loizzi V, et al
    Adjuvant chemotherapy does not improve disease-free survival in FIGO stage IC ovarian granulosa cell tumors: The MITO-9 study.
    Gynecol Oncol. 2016 Sep 3. pii: S0090-8258(16)31342.
    PubMed     Text format     Abstract available


  247. SAWAYA GF
    Cervical cancer screening in women over 65. CON: Reasons for uncertainty.
    Gynecol Oncol. 2016;142:383-4.
    PubMed     Text format    


  248. WAN YL, Beverley-Stevenson R, Carlisle D, Clarke S, et al
    Working together to shape the endometrial cancer research agenda: The top ten unanswered research questions.
    Gynecol Oncol. 2016 Sep 1. pii: S0090-8258(16)31360.
    PubMed     Text format     Abstract available


    August 2016
  249. NASSER S, Lazaridis A, Evangelou M, Jones B, et al
    Correlation of pre-operative CT findings with surgical & histological tumor dissemination patterns at cytoreduction for primary advanced and relapsed epithelial ovarian cancer: A retrospective evaluation.
    Gynecol Oncol. 2016 Aug 29. pii: S0090-8258(16)31348.
    PubMed     Text format     Abstract available


  250. KALDAWY A, Segev Y, Lavie O, Auslender R, et al
    Low-grade serous ovarian cancer: A review.
    Gynecol Oncol. 2016 Aug 28. pii: S0090-8258(16)31346.
    PubMed     Text format     Abstract available


  251. CAMPOS-PARRA AD, Padua-Bracho A, Pedroza-Torres A, Figueroa-Gonzalez G, et al
    Comprehensive transcriptome analysis identifies pathways with therapeutic potential in locally advanced cervical cancer.
    Gynecol Oncol. 2016 Aug 28. pii: S0090-8258(16)31353.
    PubMed     Text format     Abstract available


  252. CASS I, Duska LR, Blank SV, Cheng G, et al
    Stress and burnout among gynecologic oncologists: A Society of Gynecologic Oncology Evidence-based Review and Recommendations.
    Gynecol Oncol. 2016 Aug 27. pii: S0090-8258(16)31345.
    PubMed     Text format    


  253. MORSE CB, Norquist BM, Harrell MI, Agnew KJ, et al
    Neoplastic cellularity is associated with clinical and molecular features of high-grade serous ovarian carcinoma.
    Gynecol Oncol. 2016 Aug 27. pii: S0090-8258(16)31351.
    PubMed     Text format     Abstract available


  254. BRIGHTWELL RM, Grzankowski KS, Lele S, Eng K, et al
    The CD47 "don't eat me signal" is highly expressed in human ovarian cancer.
    Gynecol Oncol. 2016 Aug 25. pii: S0090-8258(16)31352.
    PubMed     Text format     Abstract available


  255. GERSHENSON DM, Frazier AL
    Conundrums in the management of malignant ovarian germ cell tumors: Toward lessening acute morbidity and late effects of treatment.
    Gynecol Oncol. 2016 Aug 25. pii: S0090-8258(16)31354.
    PubMed     Text format     Abstract available


  256. SINNO AK, Peijnenburg E, Fader AN, Temkin SM, et al
    Reducing overtreatment: A comparison of lymph node assessment strategies for endometrial cancer.
    Gynecol Oncol. 2016 Aug 24. pii: S0090-8258(16)31349.
    PubMed     Text format     Abstract available


  257. PAIK ES, Shim M, Choi HJ, Lee YY, et al
    Impact of lymphadenectomy on survival after recurrence in patients with advanced ovarian cancer without suspected lymph node metastasis.
    Gynecol Oncol. 2016 Aug 23. pii: S0090-8258(16)31347.
    PubMed     Text format     Abstract available


  258. RASMUSSEN CB, Jensen A, Albieri V, Andersen KK, et al
    Increased risk of borderline ovarian tumors in women with a history of pelvic inflammatory disease: A nationwide population-based cohort study.
    Gynecol Oncol. 2016 Aug 20. pii: S0090-8258(16)31344.
    PubMed     Text format     Abstract available


  259. MONK BJ, Poveda A, Vergote I, Raspagliesi F, et al
    Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2.
    Gynecol Oncol. 2016 Aug 18. pii: S0090-8258(16)30983.
    PubMed     Text format     Abstract available


  260. ESCOBAR PF, Ramirez PT, Garcia Ocasio RE, Pareja R, et al
    Utility of indocyanine green (ICG) intra-operative angiography to determine uterine vascular perfusion at the time of radical trachelectomy.
    Gynecol Oncol. 2016 Aug 17. pii: S0090-8258(16)31262.
    PubMed     Text format     Abstract available


  261. MOORE KN, Java JJ, Slaughter KN, Rose PG, et al
    Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis.
    Gynecol Oncol. 2016 Aug 16. pii: S0090-8258(16)31343.
    PubMed     Text format     Abstract available


  262. UPPAL S, Rice LW, Beniwal A, Spencer RJ, et al
    Trends in hospice discharge, documented inpatient palliative care services and inpatient mortality in ovarian carcinoma.
    Gynecol Oncol. 2016 Aug 16. pii: S0090-8258(16)31261.
    PubMed     Text format     Abstract available


  263. PEDERSEN K, Burger EA, Sy S, Kristiansen IS, et al
    Cost-effective management of women with minor cervical lesions: Revisiting the application of HPV DNA testing.
    Gynecol Oncol. 2016 Aug 16. pii: S0090-8258(16)31254.
    PubMed     Text format     Abstract available


  264. SMITH B, Neff R, Cohn DE, Backes FJ, et al
    The mutational spectrum of FOXA2 in endometrioid endometrial cancer points to a tumor suppressor role.
    Gynecol Oncol. 2016 Aug 15. pii: S0090-8258(16)31260.
    PubMed     Text format     Abstract available


  265. HAY CM, Courtney-Brooks M, Lefkowits C, Hagan TL, et al
    Symptom management in women with recurrent ovarian cancer: Do patients and clinicians agree on what symptoms are most important?
    Gynecol Oncol. 2016 Aug 13. pii: S0090-8258(16)31258.
    PubMed     Text format     Abstract available


  266. BEAVIS AL, Salazar-Marioni S, Sinno AK, Stone RL, et al
    Sentinel lymph node detection rates using indocyanine green in women with early-stage cervical cancer.
    Gynecol Oncol. 2016 Aug 12. pii: S0090-8258(16)31259.
    PubMed     Text format     Abstract available


  267. RENDON GJ, Echeverri L, Echeverri F, Sanz-Lomana CM, et al
    Outpatient laparoscopic nerve-sparing radical hysterectomy: A feasibility study and analysis of perioperative outcomes.
    Gynecol Oncol. 2016 Aug 9. pii: S0090-8258(16)31256.
    PubMed     Text format     Abstract available


  268. TOZZI R, Traill Z, Garruto Campanile R, Ferrari F, et al
    Porta hepatis peritonectomy and hepato-celiac lymphadenectomy in patients with stage IIIC-IV ovarian cancer: Diagnostic pathway, surgical technique and outcomes.
    Gynecol Oncol. 2016 Aug 9. pii: S0090-8258(16)31255.
    PubMed     Text format     Abstract available


  269. SMITH HJ, Pasko DN, Haygood CL, Boone JD, et al
    Early warning score: An indicator of adverse outcomes in postoperative patients on a gynecologic oncology service.
    Gynecol Oncol. 2016 Aug 6. pii: S0090-8258(16)31141.
    PubMed     Text format     Abstract available


  270. CHAO A, Wu RC, Jung SM, Lee YS, et al
    Implication of genomic characterization in synchronous endometrial and ovarian cancers of endometrioid histology.
    Gynecol Oncol. 2016 Aug 4. pii: S0090-8258(16)30985.
    PubMed     Text format     Abstract available


  271. LOPEZ-RUIZ ME, Diestro MD, Yebenes L, Berjon A, et al
    One-step nucleic acid amplification (OSNA) for the detection of sentinel lymph node metastasis in endometrial cancer.
    Gynecol Oncol. 2016 Aug 3. pii: S0090-8258(16)30977.
    PubMed     Text format     Abstract available


  272. SCHLAPPE BA, Mueller JJ, Zivanovic O, Gardner GJ, et al
    Corrigendum to "Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center" [Gynecol. Oncol. 142 (2016) 13-1
    Gynecol Oncol. 2016 Aug 2. pii: S0090-8258(16)30966.
    PubMed     Text format    


  273. ALETTI GD, Cliby WA
    Time for centralizing patients with ovarian cancer: what are we waiting for?
    Gynecol Oncol. 2016;142:209-10.
    PubMed     Text format    


    July 2016
  274. SHIH KK, Hajj C, Kollmeier M, Frey MK, et al
    Impact of postoperative intensity-modulated radiation therapy (IMRT) on the rate of bowel obstruction in gynecologic malignancy.
    Gynecol Oncol. 2016 Jul 30. pii: S0090-8258(16)30987.
    PubMed     Text format     Abstract available


  275. MELAMED A, Gockley AA, Joseph NT, Sun SY, et al
    Effect of race/ethnicity on risk of complete and partial molar pregnancy after adjustment for age.
    Gynecol Oncol. 2016 Jul 30. pii: S0090-8258(16)30988.
    PubMed     Text format     Abstract available


  276. BOGANI G, Fuca G, Maltese G, Ditto A, et al
    Efficacy of adjuvant chemotherapy in early stage uterine leiomyosarcoma: A systematic review and meta-analysis.
    Gynecol Oncol. 2016 Jul 29. pii: S0090-8258(16)30981.
    PubMed     Text format     Abstract available


  277. FRUMOVITZ M, Burzawa JK, Byers LA, Lyons YA, et al
    Corrigendum to "Sequencing of mutational hotspots in cancer-related genes in small cell neuroendocrine cervical cancer" [Gynecol. Oncol. 141 (2016) 588-591].
    Gynecol Oncol. 2016 Jul 28. pii: S0090-8258(16)30979.
    PubMed     Text format    


  278. NAHAS S, Feigenberg T, Park S
    Feasibility and safety of same-day discharge after minimally invasive hysterectomy in gynecologic oncology: A systematic review of the literature.
    Gynecol Oncol. 2016 Jul 27. pii: S0090-8258(16)30984.
    PubMed     Text format     Abstract available


  279. WANG Y, Gao C, Zhang Y, Gao J, et al
    Visfatin stimulates endometrial cancer cell proliferation via activation of PI3K/Akt and MAPK/ERK1/2 signalling pathways.
    Gynecol Oncol. 2016 Jul 26. pii: S0090-8258(16)30980.
    PubMed     Text format     Abstract available


  280. FADER AN, Habermann EB, Hanson KT, Lin JF, et al
    Disparities in treatment and survival for women with endometrial cancer: A contemporary national cancer database registry analysis.
    Gynecol Oncol. 2016 Jul 25. pii: S0090-8258(16)30978.
    PubMed     Text format     Abstract available


  281. SANTOIEMMA PP, Reyes C, Wang LP, McLane MW, et al
    Systematic evaluation of multiple immune markers reveals prognostic factors in ovarian cancer.
    Gynecol Oncol. 2016 Jul 25. pii: S0090-8258(16)30976.
    PubMed     Text format     Abstract available


  282. PETRICONE-WESTWOOD D, Lebel S
    Being a caregiver to patients with ovarian cancer: A scoping review of the literature.
    Gynecol Oncol. 2016 Jul 24. pii: S0090-8258(16)30876.
    PubMed     Text format     Abstract available


  283. KANSKA J, Zakhour M, Taylor-Harding B, Karlan BY, et al
    Cyclin E as a potential therapeutic target in high grade serous ovarian cancer.
    Gynecol Oncol. 2016 Jul 23. pii: S0090-8258(16)30982.
    PubMed     Text format     Abstract available


  284. WILSON AJ, Sarfo-Kantanka K, Barrack T, Steck A, et al
    Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib.
    Gynecol Oncol. 2016 Jul 19. pii: S0090-8258(16)30957.
    PubMed     Text format     Abstract available


  285. TOZZI R, Gubbala K, Majd HS, Campanile RG, et al
    Interval Laparoscopic En-Bloc Resection of the Pelvis (L-EnBRP) in patients with stage IIIC-IV ovarian cancer: Description of the technique and surgical outcomes.
    Gynecol Oncol. 2016 Jul 19. pii: S0090-8258(16)30837.
    PubMed     Text format     Abstract available


  286. GAO B, Lindemann K, Anderson L, Fereday S, et al
    Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome.
    Gynecol Oncol. 2016 Jul 18. pii: S0090-8258(16)30834.
    PubMed     Text format     Abstract available


  287. BROWN AJ, Shen MJ, Urbauer D, Taylor J, et al
    Room for improvement: An examination of advance care planning documentation among gynecologic oncology patients.
    Gynecol Oncol. 2016 Jul 18. pii: S0090-8258(16)30879.
    PubMed     Text format     Abstract available


  288. MOGENSEN JB, Kjaer SK, Mellemkjaer L, Jensen A, et al
    Endometriosis and risks for ovarian, endometrial and breast cancers: A nationwide cohort study.
    Gynecol Oncol. 2016 Jul 15. pii: S0090-8258(16)30964.
    PubMed     Text format     Abstract available


  289. DONOYAMA N, Satoh T, Hamano T, Ohkoshi N, et al
    Physical effects of Anma therapy (Japanese massage) for gynecologic cancer survivors: A randomized controlled trial.
    Gynecol Oncol. 2016 Jul 15. pii: S0090-8258(16)30833.
    PubMed     Text format     Abstract available


  290. WANG D, Li C, Zhang Y, Wang M, et al
    Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
    Gynecol Oncol. 2016 Jul 14. pii: S0090-8258(16)30961.
    PubMed     Text format     Abstract available


  291. YANG J, Xiang Y, Wan X, Feng F, et al
    Primary treatment of stage IV gestational trophoblastic neoplasia with floxuridine, dactinomycin, etoposide and vincristine (FAEV): A report based on our 10-year clinical experiences.
    Gynecol Oncol. 2016 Jul 14. pii: S0090-8258(16)30970.
    PubMed     Text format     Abstract available


  292. GUNDERSON CC, Ding K, Dvorak J, Moore KN, et al
    The pro-inflammatory effect of obesity on high grade serous ovarian cancer.
    Gynecol Oncol. 2016 Jul 14. pii: S0090-8258(16)30972.
    PubMed     Text format     Abstract available


  293. KONG TW, Lee JD, Son JH, Paek J, et al
    Treatment outcomes in patients with FIGO stage IB-IIA cervical cancer and a focally disrupted cervical stromal ring on magnetic resonance imaging: A propensity score matching study.
    Gynecol Oncol. 2016 Jul 14. pii: S0090-8258(16)30969.
    PubMed     Text format     Abstract available


  294. PEDROZA-TORRES A, Fernandez-Retana J, Peralta-Zaragoza O, Jacobo-Herrera N, et al
    A microRNA expression signature for clinical response in locally advanced cervical cancer.
    Gynecol Oncol. 2016 Jul 13. pii: S0090-8258(16)30962.
    PubMed     Text format     Abstract available


  295. SOARES RR, Maesta I, Colon J, Braga A, et al
    Complete molar pregnancy in adolescents from North and South America: Clinical presentation and risk of gestational trophoblastic neoplasia.
    Gynecol Oncol. 2016 Jul 13. pii: S0090-8258(16)30836.
    PubMed     Text format     Abstract available


  296. CHAN JK, Gardner AB, Chan JE, Guan A, et al
    The influence of age and other prognostic factors associated with survival of ovarian immature teratoma - A study of 1307 patients.
    Gynecol Oncol. 2016 Jul 13. pii: S0090-8258(16)30835.
    PubMed     Text format     Abstract available


  297. TALHOUK A, Hoang LN, McConechy MK, Nakonechny Q, et al
    Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment.
    Gynecol Oncol. 2016 Jul 13. pii: S0090-8258(16)30959.
    PubMed     Text format     Abstract available


  298. CIBULA D, Zikan M, Slama J, Fischerova D, et al
    Risk of micrometastases in non-sentinel pelvic lymph nodes in cervical cancer.
    Gynecol Oncol. 2016 Jul 12. pii: S0090-8258(16)30968.
    PubMed     Text format     Abstract available


  299. WONG AT, Rineer J, Lee YC, Schwartz D, et al
    Utilization of adjuvant therapies and their impact on survival for women with stage IIIC endometrial adenocarcinoma.
    Gynecol Oncol. 2016 Jul 12. pii: S0090-8258(16)30960.
    PubMed     Text format     Abstract available


  300. WATSON CH, Ulm M, Blackburn P, Smiley L, et al
    Video-assisted genetic counseling in patients with ovarian, fallopian and peritoneal carcinoma.
    Gynecol Oncol. 2016 Jul 11. pii: S0090-8258(16)30963.
    PubMed     Text format     Abstract available


  301. DE LA MOTTE ROUGE T, Pautier P, Genestie C, Rey A, et al
    Prognostic significance of an early decline in serum alpha-fetoprotein during chemotherapy for ovarian yolk sac tumors.
    Gynecol Oncol. 2016 Jul 8. pii: S0090-8258(16)30862.
    PubMed     Text format     Abstract available


  302. SLAMA J, Cerny A, Dusek L, Fischerova D, et al
    Results of less radical fertility-sparing procedures with omitted parametrectomy for cervical cancer: 5years of experience.
    Gynecol Oncol. 2016 Jul 7. pii: S0090-8258(16)30877.
    PubMed     Text format     Abstract available


  303. MARTIN JY, Goff BA, Urban RR
    Preoperative hyponatremia in women with ovarian cancer: An additional cause for concern?
    Gynecol Oncol. 2016 Jul 4. pii: S0090-8258(16)30829.
    PubMed     Text format     Abstract available


  304. ROSENBLATT KA, Osterbur EF, Douglas JA
    Case-control study of cervical cancer and gynecologic screening: A SEER-Medicare analysis.
    Gynecol Oncol. 2016 Jul 4. pii: S0090-8258(16)30827.
    PubMed     Text format     Abstract available


  305. GIANNAKEAS V, Sopik V, Narod SA
    A model for ovarian cancer progression based on inherent resistance.
    Gynecol Oncol. 2016 Jul 4. pii: S0090-8258(16)30825.
    PubMed     Text format     Abstract available


  306. WALKER JL
    Intraperitoneal chemotherapy for ovarian cancer.
    Gynecol Oncol. 2016;142:1-2.
    PubMed     Text format    


    June 2016
  307. SZUBERT S, Wojtowicz A, Moszynski R, Zywica P, et al
    External validation of the IOTA ADNEX model performed by two independent gynecologic centers.
    Gynecol Oncol. 2016 Jun 30. pii: S0090-8258(16)30831.
    PubMed     Text format     Abstract available


  308. DE LEON M, Cardenas H, Vieth E, Emerson R, et al
    Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancer.
    Gynecol Oncol. 2016 Jun 30. pii: S0090-8258(16)30828.
    PubMed     Text format     Abstract available


  309. MATSUO K, Moeini A, Machida H, Fullerton ME, et al
    Significance of venous thromboembolism in women with cervical cancer.
    Gynecol Oncol. 2016 Jun 24. pii: S0090-8258(16)30817.
    PubMed     Text format     Abstract available


  310. ATASEVEN B, Chiva LM, Harter P, Gonzalez-Martin A, et al
    FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited.
    Gynecol Oncol. 2016 Jun 19. pii: S0090-8258(16)30824.
    PubMed     Text format     Abstract available


  311. RAUH-HAIN JA, Birrer M, Del Carmen MG
    "Carcinosarcoma of the ovary, fallopian tube, and peritoneum: Prognostic factors and treatment modalities".
    Gynecol Oncol. 2016 Jun 16. pii: S0090-8258(16)30771.
    PubMed     Text format     Abstract available


  312. BARBER EL, Bensen JT, Snavely AC, Gehrig PA, et al
    Who presents satisfied? Non-modifiable factors associated with patient satisfaction among gynecologic oncology clinic patients.
    Gynecol Oncol. 2016 Jun 10. pii: S0090-8258(16)30814.
    PubMed     Text format     Abstract available


  313. ROQUE DR, Makowski L, Chen TH, Rashid N, et al
    Association between differential gene expression and body mass index among endometrial cancers from The Cancer Genome Atlas Project.
    Gynecol Oncol. 2016 Jun 8. pii: S0090-8258(16)30811.
    PubMed     Text format     Abstract available


  314. LEE J, Aphinyanaphongs Y, Curtin JP, Chern JY, et al
    The safety of same-day discharge after laparoscopic hysterectomy for endometrial cancer.
    Gynecol Oncol. 2016 Jun 8. pii: S0090-8258(16)30815.
    PubMed     Text format     Abstract available


  315. ANDRIKOPOULOU M, Vetere P, Nezhat FR
    Ovarian cancer laparoscopic hysterectomy and staging in a patient with history of intraperitoneal renal transplant.
    Gynecol Oncol. 2016 Jun 7. pii: S0090-8258(16)30812.
    PubMed     Text format     Abstract available


  316. HIJAZ M, Chhina J, Mert I, Taylor M, et al
    Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
    Gynecol Oncol. 2016 Jun 6. pii: S0090-8258(16)30773.
    PubMed     Text format     Abstract available


  317. IMAI K, Kato H, Katayama K, Nakanishi K, et al
    A preoperative risk-scoring system to predict lymph node metastasis in endometrial cancer and stratify patients for lymphadenectomy.
    Gynecol Oncol. 2016 Jun 4. pii: S0090-8258(16)30772.
    PubMed     Text format     Abstract available


  318. TSENG JH, Suidan RS, Zivanovic O, Gardner GJ, et al
    Diverting ileostomy during primary debulking surgery for ovarian cancer: Associated factors and postoperative outcomes.
    Gynecol Oncol. 2016 Jun 4. pii: S0090-8258(16)30764.
    PubMed     Text format     Abstract available


  319. FREEMAN AH, Barrie A, Lyon L, Littell RD, et al
    Venous thromboembolism following minimally invasive surgery among women with endometrial cancer.
    Gynecol Oncol. 2016 Jun 2. pii: S0090-8258(16)30770.
    PubMed     Text format     Abstract available


  320. SAWYER BT, LaFargue CJ, Bristow RE
    Extended left upper quadrant resection during primary cytoreductive surgery for Stage IV ovarian cancer.
    Gynecol Oncol. 2016 Jun 2. pii: S0090-8258(16)30769.
    PubMed     Text format     Abstract available


  321. BARBER EL, Rutstein SE, Miller WC, Gehrig PA, et al
    Corrigendum to 'A preoperative personalized risk assessment calculator for elderly ovarian cancer patients undergoing primary cytoreductive surgery' Gynecol. Oncol. 139 (2015) start 401-406.
    Gynecol Oncol. 2016 Jun 2. pii: S0090-8258(16)30767.
    PubMed     Text format    


  322. ESSELEN KM, Terry KL, Samuel A, Elias KM, et al
    Endosalpingiosis: More than just an incidental finding at the time of gynecologic surgery?
    Gynecol Oncol. 2016 Jun 2. pii: S0090-8258(16)30765.
    PubMed     Text format     Abstract available


  323. JHINGRAN A, Klopp A
    Big Data to the Rescue: Is there a benefit to combined-modality adjuvant therapy in endometrial cancer?
    Gynecol Oncol. 2016;141:403-4.
    PubMed     Text format    


  324. CRONIN B, Bregar A, Luis C, Schechter S, et al
    Evaluation of anal cytology and dysplasia in women with a history of lower genital tract dysplasia and malignancy.
    Gynecol Oncol. 2016;141:492-6.
    PubMed     Text format     Abstract available


  325. ORTON A, Boothe D, Williams N, Buchmiller T, et al
    Brachytherapy improves survival in primary vaginal cancer.
    Gynecol Oncol. 2016;141:501-6.
    PubMed     Text format     Abstract available


  326. WRIGHT JD, Chen L, Jorge S, Burke WM, et al
    Prescription of extended-duration thromboprophylaxis after high-risk, abdominopelvic cancer surgery.
    Gynecol Oncol. 2016;141:531-7.
    PubMed     Text format     Abstract available


  327. HODEIB M, Cohen JG, Mehta S, Rimel BJ, et al
    Recurrence and risk of progression to lower genital tract malignancy in women with high grade VAIN.
    Gynecol Oncol. 2016;141:507-10.
    PubMed     Text format     Abstract available


  328. LI J, Wang Z, Chen C, Liu P, et al
    Distribution of iliac veins posterior to the common iliac artery bifurcation related to pelvic lymphadenectomy: A digital in vivo anatomical study of 442 Chinese females.
    Gynecol Oncol. 2016;141:538-42.
    PubMed     Text format     Abstract available


    May 2016
  329. NEAL SA, Graybill WS, Garrett-Mayer E, McDowell ML, et al
    Lymph-vascular space invasion in uterine corpus cancer: What is its prognostic significance in the absence of lymph node metastases?
    Gynecol Oncol. 2016 May 31. pii: S0090-8258(16)30766.
    PubMed     Text format     Abstract available


  330. ZHAO S, Sebire NJ, Kaur B, Seckl MJ, et al
    Molecular genotyping of placental site and epithelioid trophoblastic tumours; female predominance.
    Gynecol Oncol. 2016 May 28. pii: S0090-8258(16)30761.
    PubMed     Text format     Abstract available


  331. GOUY S, Ferron G, Glehen O, Bayar A, et al
    Results of a multicenter phase I dose-finding trial of hyperthermic intraperitoneal cisplatin after neoadjuvant chemotherapy and complete cytoreductive surgery and followed by maintenance bevacizumab in initially unresectable ovarian cancer.
    Gynecol Oncol. 2016 May 28. pii: S0090-8258(16)30760.
    PubMed     Text format     Abstract available


  332. BROWN AJ, Shah JS, Fleming ND, Nick AM, et al
    Role of cervical cytology in surveillance after radical trachelectomy for cervical cancer.
    Gynecol Oncol. 2016 May 28. pii: S0090-8258(16)30762.
    PubMed     Text format     Abstract available


  333. ROSSI A, Garber CE, Ortiz M, Viswanathan S, et al
    Feasibility of a physical activity intervention for obese, socioculturally diverse endometrial cancer survivors.
    Gynecol Oncol. 2016 May 28. pii: S0090-8258(16)30763.
    PubMed     Text format     Abstract available


  334. HERNANDEZ L, Kim MK, Lyle LT, Bunch KP, et al
    Characterization of ovarian cancer cell lines as in vivo models for preclinical studies.
    Gynecol Oncol. 2016 May 28. pii: S0090-8258(16)30757.
    PubMed     Text format     Abstract available


  335. UPPAL S, Del Carmen MG, Rice LW, Reynolds RK, et al
    Variation in care in concurrent chemotherapy administration during radiation for locally advanced cervical cancer.
    Gynecol Oncol. 2016 May 28. pii: S0090-8258(16)30755.
    PubMed     Text format     Abstract available


  336. LIAO JB
    Immunotherapy for Gynecologic Cancers: State of the Science.
    Gynecol Oncol. 2016 May 27. pii: S0090-8258(16)30758.
    PubMed     Text format    


  337. DAHM-KAHLER P, Palmqvist C, Staf C, Holmberg E, et al
    Centralized primary care of advanced ovarian cancer improves complete cytoreduction and survival - a population-based cohort study.
    Gynecol Oncol. 2016 May 26. pii: S0090-8258(16)30754.
    PubMed     Text format     Abstract available


  338. KUMAR A, Moynagh MR, Multinu F, Cliby WA, et al
    Muscle composition measured by CT scan is a measurable predictor of overall survival in advanced ovarian cancer.
    Gynecol Oncol. 2016 May 25. pii: S0090-8258(16)30756.
    PubMed     Text format     Abstract available


  339. JORGE S, Jones NL, Chen L, Hou JY, et al
    Characteristics, treatment and outcomes of women with immature ovarian Teratoma, 1998-2012.
    Gynecol Oncol. 2016 May 21. pii: S0090-8258(16)30753.
    PubMed     Text format     Abstract available


  340. PETRILLO M, Amadio G, Salutari V, Paris I, et al
    Impact of bevacizumab containing first line chemotherapy on recurrent disease in epithelial ovarian cancer: A case-control study.
    Gynecol Oncol. 2016 May 20. pii: S0090-8258(16)30741.
    PubMed     Text format     Abstract available


  341. RANDALL TC, Goodman A, Schmeler K, Durfee J, et al
    Cancer and the world's poor: What's a gynecologic cancer specialist to do?
    Gynecol Oncol. 2016 May 19. pii: S0090-8258(16)30742.
    PubMed     Text format     Abstract available


  342. ATASEVEN B, Harter P, Grimm C, Heitz F, et al
    The revised 2014 FIGO staging system for epithelial ovarian cancer: Is a subclassification into FIGO stage IVA and IVB justified?
    Gynecol Oncol. 2016 May 18. pii: S0090-8258(16)30745.
    PubMed     Text format     Abstract available


  343. RAY-COQUARD I, Rizzo E, Blay JY, Casali P, et al
    Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chem
    Gynecol Oncol. 2016 May 18. pii: S0090-8258(16)30740.
    PubMed     Text format     Abstract available


  344. SLAUGHTER K, Holman LL, Thomas EL, Gunderson CC, et al
    Primary and acquired platinum-resistance among women with high grade serous ovarian cancer.
    Gynecol Oncol. 2016 May 18. pii: S0090-8258(16)30744.
    PubMed     Text format     Abstract available


  345. DAI D, Thiel KW, Salinas EA, Goodheart MJ, et al
    Stratification of endometrioid endometrial cancer patients into risk levels using somatic mutations.
    Gynecol Oncol. 2016 May 16. pii: S0090-8258(16)30731.
    PubMed     Text format     Abstract available


  346. POOLE EM, Konstantinopoulos PA, Terry KL
    Prognostic implications of reproductive and lifestyle factors in ovarian cancer.
    Gynecol Oncol. 2016 May 14. pii: S0090-8258(16)30733.
    PubMed     Text format     Abstract available


  347. SCHLAPPE BA, Mueller JJ, Zivanovic O, Gardner GJ, et al
    Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center.
    Gynecol Oncol. 2016 May 14. pii: S0090-8258(16)30734.
    PubMed     Text format     Abstract available


  348. HUSAIN A, Wang Y, Hanker LC, Ojeda B, et al
    Independent Radiologic Review of AURELIA, A Phase 3 Trial of Bevacizumab Plus Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer.
    Gynecol Oncol. 2016 May 13. pii: S0090-8258(16)30730.
    PubMed     Text format     Abstract available


  349. KONG TW, Kim J, Son JH, Kang SW, et al
    Preoperative nomogram for prediction of microscopic parametrial infiltration in patients with FIGO stage IB cervical cancer treated with radical hysterectomy.
    Gynecol Oncol. 2016 May 11. pii: S0090-8258(16)30683.
    PubMed     Text format     Abstract available


  350. ATRI M, Zhang Z, Dehdashti F, Lee SI, et al
    Utility of PET-CT to Evaluate Retroperitoneal Lymph Node Metastasis in Advanced Cervical Cancer: Results of ACRIN6671/GOG0233 Trial.
    Gynecol Oncol. 2016 May 10. pii: S0090-8258(16)30681.
    PubMed     Text format     Abstract available


  351. KOSKAS M, Uzan J, Vanderstraeten A, Vergote I, et al
    External validation of non-imaging models for predicting distant metastasis in patients with endometrial cancer.
    Gynecol Oncol. 2016 May 9. pii: S0090-8258(16)30687.
    PubMed     Text format     Abstract available


  352. TURNER TB, Buchsbaum DJ, Straughn JM Jr, Randall TD, et al
    Ovarian cancer and the immune system - The role of targeted therapies.
    Gynecol Oncol. 2016 May 9. pii: S0090-8258(16)30686.
    PubMed     Text format     Abstract available


  353. KARLSEN NM, Karlsen MA, Hogdall E, Nedergaard L, et al
    Relapse and disease specific survival in 1143 Danish women diagnosed with borderline ovarian tumours (BOT).
    Gynecol Oncol. 2016 May 7. pii: S0090-8258(16)30684.
    PubMed     Text format     Abstract available


  354. ZHAO J, Lv WG, Feng FZ, Wan XR, et al
    Placental site trophoblastic tumor: A review of 108 cases and their implications for prognosis and treatment.
    Gynecol Oncol. 2016 May 7. pii: S0090-8258(16)30685.
    PubMed     Text format     Abstract available


  355. VATANSEVER D, Atici AE, Sozen H, Sakin O, et al
    Diaphragmatic resection preserving and repairing pericardium, splenectomy and distal pancreatectomy for interval debulking surgery of ovarian cancer.
    Gynecol Oncol. 2016 May 7. pii: S0090-8258(16)30682.
    PubMed     Text format     Abstract available


  356. CRAFTON SM, Bixel K, Hays JL
    PARP inhibition and gynecologic malignancies: A review of current literature and on-going trials.
    Gynecol Oncol. 2016 May 7. pii: S0090-8258(16)30680.
    PubMed     Text format     Abstract available


  357. XIONG J, He M, Hansen K, Jackson CL, et al
    The clinical significance of K-ras mutation in endometrial "surface epithelial changes" and their associated endometrial adenocarcinoma.
    Gynecol Oncol. 2016 May 3. pii: S0090-8258(16)30679.
    PubMed     Text format     Abstract available


  358. ZHANG D, Bai B, Xi Y, Wang T, et al
    Is aspirin use associated with a decreased risk of ovarian cancer? A systematic review and meta-analysis of observational studies with dose-response analysis.
    Gynecol Oncol. 2016 May 2. pii: S0090-8258(16)30677.
    PubMed     Text format     Abstract available


  359. LESTER-COLL NH, Park HS, Rutter CE, Corso CD, et al
    Who benefits from chemoradiation in stage III-IVA endometrial cancer? An analysis of the National Cancer Data Base.
    Gynecol Oncol. 2016 May 2. pii: S0090-8258(16)30678.
    PubMed     Text format     Abstract available


  360. WOLFSON AH, Reis IM, Portelance L, Diaz DA, et al
    Prognostic impact of clinical tumor size on overall survival for subclassifying stages I and II vaginal cancer: A SEER analysis.
    Gynecol Oncol. 2016;141:255-9.
    PubMed     Text format     Abstract available


    April 2016
  361. STROHL AE, Feinglass JM, Shahabi S, Simon MA, et al
    Surgical wait time: A new health indicator in women with endometrial cancer.
    Gynecol Oncol. 2016 Apr 22. pii: S0090-8258(16)30146.
    PubMed     Text format     Abstract available


  362. RODRIGUEZ GC, Turbov J, Rosales R, Yoo J, et al
    Progestins inhibit calcitriol-induced CYP24A1 and synergistically inhibit ovarian cancer cell viability: An opportunity for chemoprevention.
    Gynecol Oncol. 2016 Apr 19. pii: S0090-8258(16)30154.
    PubMed     Text format     Abstract available


  363. FENG Z, Wen H, Bi R, Yang W, et al
    Prognostic impact of the time interval from primary surgery to intravenous chemotherapy in high grade serous ovarian cancer.
    Gynecol Oncol. 2016 Apr 17. pii: S0090-8258(16)30148.
    PubMed     Text format     Abstract available


  364. EGGINK FA, Mom CH, Kruitwagen RF, Reyners AK, et al
    Improved outcomes due to changes in organization of care for patients with ovarian cancer in the Netherlands.
    Gynecol Oncol. 2016 Apr 15. pii: S0090-8258(16)30140.
    PubMed     Text format     Abstract available


  365. FRUMOVITZ M, Burzawa JK, Byers LA, Lyons YA, et al
    Sequencing of mutational hotspots in cancer-related genes in small cell neuroendocrine cervical cancer.
    Gynecol Oncol. 2016 Apr 11. pii: S0090-8258(16)30102.
    PubMed     Text format     Abstract available


  366. KOBEL M, Atenafu EG, Rambau PF, Ferguson SE, et al
    Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study.
    Gynecol Oncol. 2016 Apr 9. pii: S0090-8258(16)30109.
    PubMed     Text format     Abstract available


  367. ZHOU Y, Irwin ML, Ferrucci LM, McCorkle R, et al
    Health-related quality of life in ovarian cancer survivors: Results from the American Cancer Society's Study of Cancer Survivors - I.
    Gynecol Oncol. 2016 Apr 9. pii: S0090-8258(16)30106.
    PubMed     Text format     Abstract available


  368. CLARK LH, Jackson AL, Soo AE, Orrey DC, et al
    Extremes in body mass index affect overall survival in women with cervical cancer.
    Gynecol Oncol. 2016 Apr 4. pii: S0090-8258(16)30091.
    PubMed     Text format     Abstract available


  369. NOER MC, Sperling CD, Antonsen SL, Ottesen B, et al
    A new clinically applicable age-specific comorbidity index for preoperative risk assessment of ovarian cancer patients.
    Gynecol Oncol. 2016 Apr 4. pii: S0090-8258(16)30090.
    PubMed     Text format     Abstract available


  370. MUNKARAH A, Mert I, Chhina J, Hamid S, et al
    Targeting of free fatty acid receptor 1 in EOC: A novel strategy to restrict the adipocyte-EOC dependence.
    Gynecol Oncol. 2016;141:72-9.
    PubMed     Text format     Abstract available


  371. ROMA AA, Mistretta TA, Diaz De Vivar A, Park KJ, et al
    New pattern-based personalized risk stratification system for endocervical adenocarcinoma with important clinical implications and surgical outcome.
    Gynecol Oncol. 2016;141:36-42.
    PubMed     Text format     Abstract available


  372. KYRGIOU M, Pouliakis A, Panayiotides JG, Margari N, et al
    Personalised management of women with cervical abnormalities using a clinical decision support scoring system.
    Gynecol Oncol. 2016;141:29-35.
    PubMed     Text format     Abstract available


  373. JANCO JM, Kumar A, Weaver AL, McGree ME, et al
    Performance of AGO score for secondary cytoreduction in a high-volume U.S. center.
    Gynecol Oncol. 2016;141:140-7.
    PubMed     Text format     Abstract available


    March 2016
  374. MANLEY KM, Wills AK, Morris GC, Hogg JL, et al
    The impact of HPV cervical screening on negative large loop excision of the transformation zone (LLETZ): A comparative cohort study.
    Gynecol Oncol. 2016 Mar 28. pii: S0090-8258(16)30088.
    PubMed     Text format     Abstract available


  375. HOLST S, Wohlfahrt J, Kjaer SK, Kamper-Jorgensen M, et al
    Cervical cancer screening in Greenland, 1997-2011: Screening coverage and trends in the incidence of high-grade cervical lesions.
    Gynecol Oncol. 2016 Mar 23. pii: S0090-8258(16)30085.
    PubMed     Text format     Abstract available


  376. BACKES FJ, Fowler JM
    Late side effects of robotic surgery.
    Gynecol Oncol. 2016;140:375-6.
    PubMed     Text format    


  377. VAN DOORN HC, van Beekhuizen HJ, Gaarenstroom KN, van der Velden J, et al
    Repeat sentinel lymph node procedure in patients with recurrent vulvar squamous cell carcinoma is feasible.
    Gynecol Oncol. 2016;140:415-9.
    PubMed     Text format     Abstract available


  378. ROBERTSON NL, Hricak H, Sonoda Y, Sosa RE, et al
    The impact of FDG-PET/CT in the management of patients with vulvar and vaginal cancer.
    Gynecol Oncol. 2016;140:420-4.
    PubMed     Text format     Abstract available


    February 2016
  379. BRADFORD A, Shinn E
    Incorporating Patient Perspectives and Priorities into Clinical Trial Design.
    Gynecol Oncol. 2016;140:191-2.
    PubMed     Text format    


  380. ALVAREZ RD, Huh WK, Bae S, Lamb LS Jr, et al
    A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3).
    Gynecol Oncol. 2016;140:245-52.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: